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ABSTRACT OF DISSERTATION

ROLE OF MATRIX METALLOPROTEINASE-2 IN ATHEROSCLEROSIS
AND ABDOMINAL AORTIC ANEURYSMS IN APOLIPOPROTEIN E
DEFICIENT MICE
Matrix metalloproteinase-2 (MMP-2, gelatinase A, type IV collagenase) is
a member of a family of zinc-dependent metalloendopeptidases that functions in
the degradation of elastin, collagens, and other components of extracellular
matrix (ECM). Both secretion and activation of MMP-2 are elevated in human
atherosclerotic lesions and abdominal aortic aneurysms (AAA). In this
dissertation project, we sought to test the hypothesis that MMP-2 plays a critical
role in both atherosclerosis and AAA. We also sought to determine the detailed
mechanism. We first examined the atherosclerosis and AngII-induced AAAs
development in MMP-2-/- x apolipoprotein (apoE)-/- mice in vivo. It was
surprising that MMP-2 deficiency did not reduce the incidence of AngII-induced
AAAs or the size of atherosclerosis in apoE-/- mice. However, the cellular and
ECM content of atherosclerotic plaques were modified in MMP-2-/- x apoE-/mice as compared to MMP-2+/+ x apoE-/- control mice. To explain the apparent
paradox between this result and the hypothesis, we investigated the
morphological characteristics of the aortic wall of MMP-2-/- mice. We detected an

enhanced MMP-9 level in the aortic wall of MMP-2-/- x apoE-/- mice compared
with MMP-2+/+ x apoE-/- mice. Interestingly, we also observed more branching
of the elastin fibers in aortic wall of MMP-2-/- mice as compared with aorta of wild
type mice. We also examined the behavior of macrophages from MMP-2-/- mice.
Reduced adhesion, migration, and expression of integrin beta 3 were detected in
MMP-2 deficient macrophages compared with wild type macrophages. Lastly, we
examined whether MMP-2 deficiency in bone marrow-derived cells may influence
AAAs and atherosclerosis using bone marrow transplantation technique. There
was a significant reduction of both atherosclerosis development and AAAs
formation in mice that were reconstituted MMP-2-/- bone marrow cells. In
conclusion, the findings in this dissertation suggest that MMP-2 might play an
important role in atherosclerosis and aneurysm through influencing inflammatory
cell infiltration.
KEYWORDS: matrix metalloproteinase-2, atherosclerosis, abdominal aortic
aneurysm, integrin, macrophage
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Chapter One
Introduction
I. Atherosclerosis
Atherosclerosis
Atherosclerosis is traditionally described as a condition that involves the
deposition of lipids in the tunica intima and deep layers of large and mediumsized arteries. These lipid deposits, along with other substances, form plaques
which tend to diminish arterial elasticity and may result in a narrowing or
blockage of the lumen in some arteries. However, the hardening of the arteries
often occurs in advanced stages and is not a predominant feature of
atherosclerosis. The plaque formation constricts the blood flow and ultimately
deprives the blood supply to vital organs. Based on an official survey, coronary
heart disease (CHD), the most common form of heart disease, was the leading
cause of death (2,443,387 deaths; 241.7/population of 100,000) in the USA for
2002.112 The same survey indicated that stroke, which is another major
complication of atherosclerosis, was the third leading cause of death accounting
for 162,672 deaths (56.4/population of 100,000).112

Pathogenesis
According to many epidemiological reports, a series of etiologic agents
including cigarette smoking, dietary fat, sex hormones, and oxidative stress are
associated with the initiation and progression of atherosclerosis. Genetic factors
are also important in the development of atherosclerosis. For example, carriers of
the polymorphism apo (apolipoprotein) E4 alleles have a greater risk of
cardiovascular diseases than individuals with the apoE3/3 genotype. Genomic
instability associated with loss of heterozygosity and mutations in DNA micro
1

satellites have been implicated in the initiation and extension of plaques.5
Multiple genetically predisposed diseases or conditions are closely related to
atherosclerosis as well, such as some dyslipidemias, diabetes mellitus, and
hypertension.

Pathological processes
Although the exact biological process of atherosclerosis is not fully
understood, three different stages of atherosclerosis have been described – the
“fatty streak” stage, the fibrous plaque stage, and the complicated lesion stage.
The appearance of a viscous, yellow streak running along the endothelial surface
of the arteries is the earliest pathological stage of atherosclerosis. It is the result
of accumulation of serum lipoproteins within the intima of the vessel wall.
Microscopy reveals that varying proportions of lipid-laden foam cells (monocytederived macrophages), T lymphocytes, and smooth muscle cells constitute these
“streaks.” The lesions are focal, small, and non-obstructive. As the disease
advances into the second stage, the fatty streak may progress to form a fibrous
plaque, which is the result of progressive lipid accumulation and the migration
and proliferation of smooth muscle cells. These smooth muscle cells are
responsible for the deposition of extracellular matrix (ECM) components and
formation of a fibrous cap that overlies a core of lipid-laden foam cells,
extracellular lipid, and necrotic cellular debris. Growth of the fibrous plaque
results in vascular remodeling, progressive luminal narrowing, blood-flow
abnormalities, and usually compromises oxygen supply to the target organ. The
last stage of atherosclerosis, the complicated lesion stage, is described as a
calcified fibrous plaque containing various degrees of necrosis and ulceration,
and is frequently associated with symptoms. With increasing necrosis in the
fibrous plaque, the arterial wall progressively weakens. Should the plaque
rupture, the cholesterol and connective tissue underneath might be exposed.
Consequently, rupture provokes strong blood clotting reactions, thus arterial
2

emboli can be formed.
With the advancement of cardiovascular biology, the understanding of
atherosclerosis has evolved rapidly over the past three decades. To date,
atherosclerosis has been well characterized by endothelial dysfunction, intimal
thickening, vascular smooth muscle cell (VSMC) proliferation, lipid deposition,
cholesterol-laden foam cell (monocyte-derived macrophage) development,
inflammatory cell accumulation, vascular matrix remodeling, excess generation of
reactive oxygen species (ROS) and platelet activation and thrombosis. The
balance of systemic and local inflammatory and anti-inflammatory cellular and
molecular elements play a pivotal role in all phases of plaque development,
progression,

and

degeneration.42,138,143,170

Therefore,

the

infiltration

and

accumulation of inflammatory cells, especially macrophages, are critical events in
the development of atherosclerosis. The autopsies of patients who have died of
acute coronary disease reveal that macrophage infiltration and accumulation
have a consistently positive relationship with plaque rupture.55 Although the uptake of oxidatively modified LDL (ox-LDL) by macrophages and their subsequent
exit from the lesion might be anti-atherogenic in the early stage of
atherosclerosis, macrophages produce a diverse array of atherogenic cytokines,
chemoattractants, and proteolytic enzymes including matrix metalloproteinases
(MMPs), which can degrade all macromolecular constituents of the ECM in the
vascular wall.
There are several hypotheses concerning the initiation of atherosclerosis.
The first proposes a “response-to-injury” scenario where injury to endothelial and
smooth muscle cells triggers initial events that lead to atherosclerosis. Another
hypothesis, oxidation, focuses on the significance of the oxidative modification of
low density lipoprotein (LDL) in subsequent atherogenic responses, such as
inducing the synthesis of monocyte chemo-tactic protein-1 (MCP-1) which then
induces the recruitment of inflammatory cells to lesion areas. A third proposal,
“response-to-retention”, places emphasis on the subendothelial retention and
accumulation of LDL and other atherogenic lipoproteins in arteries as the primary
3

factor for initiating cholesterol-induced atherosclerosis.192 Intensive studies have
been done to understand the molecular mechanisms underlying the progression
of

atherosclerosis.

Many

molecular

pathways

in

the

progression

of

atherosclerosis have been defined: 1) alterations of transforming growth factor
(TGF)-beta, TGF-beta receptors, and Smad signaling proteins (their name comes
from the TGF-beta homologs found in C. elegans (“Sma”) and drosophila).13,140
2) alterations in several other peptide growth factors that regulate cell cycle and
proliferation in atherosclerosis including epidermal growth factor (EGF), fibroblast
growth factor (FGF), platelet-derived growth factor (PDGF), insulin-like growth
factor

(IGF),

granulocyte

macrophage

colony

stimulating

factor

(GM-

CSF).147,149,195 3) the altered expression of cell adhesion molecules, such as
integrins and selectins, which serve as promoters of atherosclerosis.28,71 4) the
involvement of proteases and tissue protease inhibitors in the progression of
atherosclerosis by contributing to luminal thrombosis.186 5) the deregulation of
nuclear factor kappa B (NF-κB). NF-κB is a transcription factor involved in the
regulation and expression of a diverse array of chemokines, cytokines, growth
factors, cell adhesion molecules, and cell cycle regulatory proteins. NF-κB
signaling also up-regulates the expression of pro-apoptotic proteins such as Bcl2, and down-regulates the expression of anti-apoptotic proteins such as
Bax.9,25,34 6) the alteration of MMP activity, which is associated with the aberrant
regulation of ECM remodeling, leading to atherosclerosis.18,67

II. Abdominal aortic aneurysms
Abdominal aortic aneurysms
An aneurysm is defined as a localized, blood-filled, and permanent
dilatation of a blood vessel caused by a disease or weakening of the vascular
wall. The word aneurysm is derived from the Greek word for “widening”.
Connective tissue diseases such as Marfan, Ehlers-Danlos’, and Stickler
4

syndrome as well as aging, and mycosis are associated with aneurysm
formation.
Abdominal aortic aneurysm (AAA) is a chronic, degenerative disease
characterized by the progressive weakening and irreversible expansion of the
abdominal aortic wall. In 1991, the Society for Vascular Surgery and the
International Society Cardiovascular Surgery Ad Hoc Committee on Standards in
Reporting developed a criterion for AAA, stating the infra-renal abdominal aortic
diameter should be more than 150% of the expected normal diameter. AAAs are
prevalent in aged populations (2-9% of people >65 years of age) with rupture
causing approximately 15,000 unexpected deaths every year in USA.84 The
incidence of AAA has increased dramatically in recent decades. Factors that may
have contributed to this increase include the increasing mean age of the
population and improvements in diagnostic evaluation. Although there is
variability between patients in the rate of aortic dilation and the point of rupture,
the available method of reducing associated mortality is still the detection of
AAAs before rupture, followed by repair of the damaged aorta.

Pathogenesis
Although the etiology of AAAs is unknown, several population-based
studies and relative hazard risk assessment evaluations indicate that the
development of AAA is significantly related to multiple factors: smoking,
advanced age, male gender, and a family history. There are conflicting reports
concerning the association between AAA, dyslipidemia, and hypertension. 3,115,210
Traditionally, atherosclerosis is believed to contribute to the formation of AAAs; a
relationship that is supported by population studies. 11,79 However, these studies
could not distinguish causal effects and associated risk factors. In addition,
evidence indicates that atherosclerosis is not the cause of AAAs because many
patients developed severe atherosclerotic lesions in their aortas without
aneurysm formation.200 Regarding family history, although the frequency of AAAs
5

in first-degree relatives is much higher when compared to the unrelated
population, a genetic basis for this disease remains unclear.

Pathological processes
Traditional concepts of AAAs emphasize the degenerative thickening and
dilation of the aortic wall. Immunohistochemistry and molecular biology
experiments with human aneurysmal tissue obtained during surgery have
consistently demonstrated large numbers of inflammatory cells in the aortic wall,
increased cytokine and protease activity, and elevated levels of cellular
production pro-apoptosis genes (such as p53 and p21) in vascular smooth
muscle cells (VSMCs).76,148,201 MMPs and fibrinolytic enzymes are found to be
more active in aneurysmal tissues than in occlusive atherosclerotic tissues. The
upregulation of these proteases is believed to be responsible for the destruction
of the elastin and collagen structural matrix.21,63 Moreover, the physiological
inhibitors of these proteases, such as TIMP-2 and PAI-1, have decreased
expression in AAA tissue. When factors such as accumulated inflammatory cells,
vascular matrix turnover by highly activated proteolytic enzymes and depletion of
VSMCs are present, their combined actions weaken the structural matrix of the
abdominal aortic wall, leading to aneurysmal dilation under the high transmural
pulse of the aorta. Consequently, these changes are accompanied by thrombus
formation in many cases.
Many studies suggest that the hallmark pathology of AAAs is the
progressive and irreversible degeneration of the medial elastic lamellae. This
destruction of elastic lamellae is considered to contribute to the aneurysmal
dilation and enlargement. However, the vessel wall remodeling occurs by
mechanisms that are different from any of the risk conditions mentioned
previously.8

6

III. Matrix metalloproteinase-2 (MMP-2)
General information regarding MMPs
The matrix metalloproteinase (MMP) family is composed of over 30
endopeptideases in which at least 17 are human MMPs. These enzymes share
some common features: they have the ability to cleave various macromolecules
of the ECM; they are comprised of the calcium and zinc ions necessary for
catalytic activity; they are produced and secreted as latent forms, except for
MMP-11, 27 and MT-MMPs; and they are inhibited by their endogenous
inhibitors, i.e., tissue inhibitor of matrix metalloproteinases (TIMPs). MMPs are
classified into 6 subgroups based on their substrate specificity and internal
homologies (Figure 1.1): collagenases (MMP-1, -8, -13, -18), gelatinases (MMP2, -9), stromelysins (MMP-3, -10, -11, -19), matrilysins (MMP-7, -26), membranetype MMPs (MT-MMPs: MMP-14, -15, -16, -17, -24, -25), and non-classified
MMPs (MMP-12, -20, -21, -22, -23, -27, -28). They are involved in extracellular
matrix degradation in many physiological and pathological processes such as
wound

healing,

ovulation,

cancer

metastasis,

and

inflammatory

joint

diseases.70,190,206 They may be implicated in cardiovascular diseases such as
atherosclerosis and AAAs as well. At least 14 MMPs have been characterized in
vascular cells.147 The gelatinases (i.e. MMP-2 and MMP-9) have attracted
attention for their elastolytic capabilities and increased levels in lesions of
vascular diseases.
Many MMPs are highly expressed in AAAs and atherosclerotic lesions. It
is believed that MMPs are involved in the destruction of the ECM and are harmful
in vascular diseases such as AAAs and atherosclerosis. However, more
evidence suggests that the role of MMPs is not limited in turnover of the ECM
components. Actually, they have multiple substrates that are involved in the
control of cellular behavior. Therefore, new evaluations of these enzymes should
be performed to elucidate the underlying mechanisms in more detail. There are
7

several studies demonstrating direct genetic evidence of the role of MMPs and
their inhibitors in vascular diseases. A few relevant conclusions are: MMP-1
transgenic

mice

on

an

apoE-/-

background

demonstrated

decreased

atherosclerotic lesions. This suggests that the remodeling of the neointimal ECM
by MMP-1 is beneficial in atherosclerosis;117 MMP-2 deficiency reduced intimal
hyperplasia in a mouse carotid artery blood flow cessation model;101,114 MMP-3
inactivation increased the size of atherosclerotic lesions and decreased the
formation of aneurysm in apoE null mice;183 MMP-9 deficiency but not MMP-12
deficiency reduced AAA formation induced by elastase perfusion in mice;162
deficiency of MMP-9, MMP-2, and MMP-12 reduced AAA formation induced by
abluminal application of calcium chloride in mice;126,125 MMP-9 deficiency, but not
MMP-12 deficiency, protected against atherosclerotic plaque growth; both
deficiency of MMP-9 and 12 protected against atherosclerotic media destruction
and ectasia in apoE null mice;129 TIMP (tissue inhibitor of MMPs)-1 inactivation
prevents development of atherosclerosis, but enhances aneurysm formation

182

in apoE null mice; Lemaitre et al. reported that TIMP-1 deficiency caused an
increased medial degradation with pseudo-aneurysm formation in apoE-/mice.118

MMP-2
The structure of the MMP-2 protein: MMP proteins have high sequence
homology. Almost all of the MMP proteins contain the following domains:

a

signal sequence; a pro-peptide domain with a strictly conserved cystine residue
which contains a Zn-ligating thiol (SH) group; a catalytic domain with a Zn
binding site and a hemopexin-like C’ terminal domain which contains four repeats
(Figure 1.2). The only exception are the matrilysins, the smallest members of
MMPs family, which do not have the hemopexin-like domain.78 Gelatinases
(MMP-2 and 9) have 3 contiguous fibronectin type II-like domains, which may
contribute to specificity in substrate binding of these enzymes.144 MMP-2, a 72
8

kDa protein, is called a gelatinase A or type IV collagenase because of its
substrates.
MMP-2 gene expression: Unlike other MMPs, MMP-2 is primarily
expressed by many cells, including VSMCs,63 macrophages,180, 213 fibroblasts, 154
endothelial cells,91 myocytes,33 mast cells,56 and lymphocytes.54 The promoter
region of MMP-2 is unique because of the absence of the TATA and CAAT box.89
It also lacks an upstream transforming growth factor (TGF) beta inhibitory
element (TIE).135 This suggests that MMP-2 is essentially a "housekeeping"
gene. Therefore, the transcription of MMP-2 gene is rarely suppressed. For
example, TGF-beta, a regulator of many MMPs, actually upregulates MMP-2
mRNA levels and increases the half-life of MMP-2 mRNA in human fibroblasts.154
Many other cytokines can upregulate MMP-2 gene expression, especially under
pathological conditions such as inflammation. For instance, granulocytemacrophage colony-stimulating factor (GM-CSF) upregulates MMP-2 expression
at both the transcription

202

and translation levels

194

in head and neck cancer

cells. Interleukin (IL)-12 and IL-18 enhance MMP-2 mRNA levels separately and
synergistically in monocytic cells.1 Also, Eichler et al. and Kim et al. showed TGFalpha enhanced MMP-2 expression in mouse blastocysts and human retinal
pigment epithelial cells,50,108 while Cipollone et al. showed that macrophage and
smooth muscle cell PGE2 increases the production of MMP-2 in the vascular
wall.32
The activation of MMP-2: As with other members of the MMP family,
MMP-2 is synthesized as a latent zymogen.

MMP-2 does not undergo

spontaneous activation.110 The pro-domain is critical for keeping MMP-2 in the
inactive state. The thiol group of the conserved cystine of the pro-domain binds
to the catalytic zinc atom in the active site of the catalytic domain, thus keeping
the enzyme inactive. The proteolytic removal of the pro-domain at Asn37-Leu38
is essential for the activation of MMP-2. After the removal of the pro-domain by
chemicals or other proteases, the catalytic cleft is exposed to water to hydrolyze
and disrupt the interaction of the thiol group (SH) of the conserved cysteine
9

residue in the pro-domain to the Zn atom.191 Under physiological conditions,
proMMP-2 is fundamentally expressed, but stable at low concentrations through
the control of activation or inhibition by TIMP-2.
MMP-2 has a unique cell surface mode of activation in which it forms a
ternary complex with MMP-14 (MT1-MMP) and TIMP-2. The N-terminal of TIMP2, which has the inhibitory ability, binds to the catalytic domain of MMP-14, and
the C'-terminal of TIMP-2 binds to the hemopexin-like domain of proMMP-2.
Since MMP-14 anchors to the plasma membrane through the transmembrane
domain and leaves the catalytic domain exposed extracellularly, the formation of
this ternary complex allows proMMP-2 to localize at the cell surface. Once
formed, it is cleaved and activated by a TIMP-free active MMP-14 molecule that
localizes nearby

100

. Therefore, TIMP-2 is required for MMP-2 activation at low

concentrations (Figure 1.3). As mentioned above, at high concentrations, TIMP-2
binds to a binding site of activated MMP-2 and reduces the activity of MMP-2.
TIMP-2 also inhibits the activation of proMMP-2 by blocking all active MMP-14.
Additional, several integrins, including alpha 2 beta 1 and alpha v beta 3,
facilitate this process via anchoring the hemopexin domain of proMMP-2 on the
cell surface.184 It was reported that MMP-14 may activate alpha v beta 3 integrin
through proteolytic cleavage.45
Following the initial removal of the pro-peptide to give a 64-kDa
intermediate, the final processing to the fully active form of 62-kDa MMP-2
requires a further proteolytic cleavage at Asn80-Phe81 by another fully activated
MMP-2 molecule.193 Integrin alpha v beta 3 may promote this by providing a
platform for autocatalytic interaction between the two MMP-2 molecules.46
Mature MMP-2 can either bind to another cell surface anchor protein or be
released. Besides the major activation pathway as described above, there are
several other pathways that contribute to the activation of MMP-2. It was reported
that proMMP-2 could be activated by physiological concentrations of uPAplasmin through a mechanism independent of the action of other metallo-or acid
proteinases.139 Two coagulation factors, thrombin and factor Xa, have been
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demonstrated to activate proMMP-2 in cultured VSMCs.66,165 Rajagopalan et al.
reported the activity of pro-MMP-2 is upregulated by ROS produced by
macrophage-derived foam cells.164 There is evidence that NF-κB, a critical
inflammatory factor, induces the activation of MMP-2.158,159 In addition,
osteopontin deficiency led to a decreased activity of both MMP-2 and MMP-9,20
and AngII-induced MMP-2 release from endothelial cells is mediated by TNFalpha.7 More recently, it was reported that in macrophages, oxidized LDLs (oxLDLs) markedly elevated the levels of MMP-14 mRNA and protein.166 However,
the cross-talk between cell signaling pathways in MMP-2 activation is poorly
understood.
The inhibition, catabolism, and clearance of MMP-2: The synthesis of
MMP-2 is hardly suppressed at the transcription and post-transcription levels.
Since MMP-2 is synthesized as a zymogen, the regulation of MMP-2 is mainly
through regulation of the activity and/or activation of the enzyme. It should be
kept in mind that proMMP-2 is stable under physiological conditions, i.e. the
zymogen is not activated spontaneously. Mature MMP-2 molecules released
from the cell surface may either maintain their active state or be inhibited by
binding to TIMP-2, which is the endogenous inhibitor of MMP-2. The MMP2/TIMP-2 complex retains 10% of proteolytic activity of MMP-2. In addition, at
high levels, TIMP-2 regulates the activation of pro-MMP-2 by blocking all active
MT1-MMP.92 The fibronectin type II domain of MMP-2 interacts with
thrombospondin properdin-like repeat (TSR) domain of thrombospondins (TSPs)
to form a complex.217 Endocytosis of the MMP-2/ TSP-2 complex, mediated by
low density lipoprotein-related receptor protein (LRP) scavenger receptor, is
another mechanism of MMP-2 control.218 The LRP mediated endocytosis is
regulated by a 39 kDa LRP-associated protein (RAP), which binds and
antagonizes the function of LRP and other members of the LDL receptor family.
LRP also mediates the clearance of the proMMP-2/TIMP-2 complex through a
TSP independent pathway.51 More recently, it was reported that furin, which is a
serine protease, directly cleaves proMMP-2 within the trans-Golgi network (TGN)
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to create an inactive form MMP-2 (63 kDa). This 63 kDa inactive MMP-2 cannot
be further cleaved to an active form.22

Substrates of MMP-2
ECM components: The three-dimensional organization of the ECM
molecules,

including

elastin,

collagen,

proteoglycans

and

structural

glycoproteins, is optimal for the function of vessel walls. ECM components can
be degraded and removed by proteolytic enzymes (especially MMPs) and cell
(such as macrophages and fibroblasts) phagocytosis. MMP-2 has various ECM
substrates including native collagen types (I, IV, V, VII, X, XI), denatured
collagens (gelatin), elastin, fibronectin, laminin-5, aggrecan, brevican, neurocan,
decorin, and vitronectin. Among these ECM molecules, fibronectin, vitronectin,
and laminin are structural glycoproteins that have a multi-domain structure and
enable interactions between cells and ECM constituents.29 Collagen and elastin
are the major protein components of vascular wall. The three repeats of
fibronectin type II inserts in the catalytic domain of MMP-2 are required to bind
and cleave collagen and elastin. 144
Regulators of cell behavior: The ECM not only provides a structural
framework to support cell adhesion and tissue integrity, but it also controls cell
behavior by influencing signaling molecules. The ECM serves as a reservoir for
many cytokines and chemokines that may affect cell adhesion and migration to
their destined sites. When the ECM is degraded, these molecules are released.
For example, TGF-beta can be released after degradation of the collagenassociated proteoglycan decorin, which is an anchor protein of TGF-beta.95
Several MMPs (including MMP-2) may release TGF-beta through this pathway.
MMP-2 and MMP-9 may proteolytically cleave and activate latent TGF-beta.219
Moreover, MMP-2 may modulate the activity of fibroblast growth factor (FGF) by
cleavage of the FGF receptor-1.119 MMP-2, by binding to IGF and inhibiting its
activity, may degrade insulin-like growth factor binding protein (IGFBP), which
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may enhance the activity of IGF. In addition, MMP-2 is involved in the activation
of endothelin-1 (ET-1). MMP-2 may cleave the Gly32-Leu33 bond of latent ET-1
(1-38) forming the potent vasoconstrictor ET-1 (1-32). This may increase cell
adhesion ability through regulating endothelial expression of adhesion molecules
such as E-selectin and intracellular adhesion molecule (ICAM).58 Furthermore,
active ET-1 produced by MMP-2 upregulates CD11b/CD18 expression on human
neutrophils.59 It was reported that MMP-2 was involved in the shedding of
vascular cell adhesion molecule (VCAM-1) directly as well.91
Involvement in the expression and activation of other MMPs: It is
known that the active form of MMP-2 can activate proMMP-9 on the surface of
cancer cells. 65 On the contrary, Esparza et al. reported that the MT1-MMP/TIMP2/MMP-2 complex, while facilitating activation of proMMP-2, could be involved in
the regulation of MMP-9 expression.53 Although these findings suggest MMP-2
may play several roles in the regulation of MMP-9 activity, the factors controlling
these effects are largely unknown. MMP-2 also facilitates MMP-14 processing
and activating the zymogen form of MMP-13.111

IV. Potential mechanisms of

MMP-2 involvement in the

development of atherosclerosis
Both secreted and active MMP-2 are elevated in human atherosclerotic
lesions.141,156 Due to lack of a selective MMP-2 inhibitor, MMP-2 deficient mice
have been created to determine the role of MMP-2 in atherosclerosis. As
mentioned above, MMP-2 deficient mice have reduced intimal hyperplasia in
mouse carotid artery blood flow cessation model. 101,114

MMP-2 is involved in the remodeling of the vascular wall
The ECM of the vascular wall is a complex network is comprised of many
high molecular weight proteins and polysaccharides. These molecules are
13

organized according to which cells secreted them. The surrounding cells are also
involved in the organization of ECM molecules. The three-dimensional structure
of the ECM provides a support for cell adhesion, facilitating tissue integrity of
vascular walls. Furthermore, the ECM may modulate signaling pathways that
control numerous cellular behaviors including growth, differentiation, survival and
morphogenesis.128 The ECM also serves as a reservoir for growth factors and a
binding site of lipoprotein, which contributes to the accumulation and oxidation of
LDL particles in the arterial wall. Turnover of ECM plays a key role in
cardiovascular diseases, including atherosclerosis and AAAs.122 As mentioned
previously, MMP-2 has various substrates of ECM components. Among these
ECM molecules, collagen and elastin are the major protein components of the
vascular wall. In particular, type I collagen is the major (60%) fibrillar collagen
detectable in blood vessels.137 Elastin is the most abundant protein in the large
arteries, and strengthens the aortic wall against pulse waves. The disruption of
elastin not only leads to dissection of arteries, but also contributes to proliferation
of VSMCs and obstructive arterial diseases.120 Other molecules involved are
fibronectin, vitronectin and laminin, and structural glycoproteins which have a
multi-domain structure and enable interactions between cells and ECM
constituents.29

MMP-2 is involved in inflammatory cell adhesion and migration
Inflammatory cell recruitment and invasion are critical for the initiation and
progression of atherosclerosis. Although macrophage accumulation is especially
important for ox-LDL clearance, accumulation of lipid-laden foam cells results in
increased size of atherosclerosis, cell death and necrotic core formation. MMP-2
facilitates cell migration in pathological processes.69,114 In mice, MMP-2
deficiency has been shown to suppress VSMC migration from the media to the
intima of the vessel wall.101,114 Some studies suggest MMP-2 might influence
neutrophil-endothelial adhesion by cleaving the latent endothelin-1 (ET-1),
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creating the potent ET-1 and upregulating CD11b/CD18 expression.58,59 Since
the recruitment of macrophages is one of the initial steps of atherosclerosis
development, MMP-2 might play an important role in the early stages of
atherosclerosis.

MMP-2 is involved in platelet aggregation
Intravascular thrombosis is one of the most crucial pathological events in
various cardiovascular diseases. Thrombosis deteriorates the hardening and
narrowing of blood vessels as well as turbulent blood flow formation and
therefore exacerbates vascular diseases. An injury to the surface of a blood
vessel attracts platelet aggregation and leads to primary thrombus formation.
Von Willebrand factor (vWF), a long-chain macromolecule, induces the activation
of platelet glycoproteins (GPs) such as GPIb and GPIIb/IIIa (fibrinogen receptor).
These glycoproteins mediate the mechano-chemical interactions between
platelet-platelet and platelet-vascular wall and consequently lead to platelet
adhesion and aggregation. During platelet aggregation, MMP-2 is translocated
from the cytosol to the platelet surface and is released.174 Solid phase vWF
induces the release of MMP-2 from platelets. Human recombinant MMP-2
potentiated the effects of vWF on platelet adhesion via upregulating GPIb. An
inhibition of MMP-2 reduced platelet adhesion when stimulated with svWF also
suggests the important role of MMP-2 in platelet aggregation.163 Thus, MMP-2
might be involved in atherosclerosis progression via influencing platelet
aggregation and thrombus formation.

MMP-2 is involved in growth factor activity
The potential roles of growth factors in cardiovascular pathophysiology
have raised considerable interest. For instance, it was reported that
transplantation of bone marrow-derived cells containing T cells with dominant15

negative TGF-beta receptors led to a reduced size of atherosclerotic lesions but
increased vulnerability to rupture in LDLr-/- mice.73 MMP-2 is known to
proteolytically cleave and activate TGF-beta.95 MMP-2 might cleave decorin,
which is an anchor protein of TGF-beta, thus releasing TGF-beta. 219 MMP-2 also
increases the availability of insulin-like growth factor (IGF) by degrading the IGF
binding proteins.62 Furthermore, MMP-2 cleaves cell surface fibroblast growth
factor (FGF) receptor-1 and releases the soluble FGF receptor into circulation.
This soluble FGF receptor fragment is able to bind to FGF and might indirectly
influence FGF availability. It is not known whether the removal of FGF receptors
could influence cell response to FGF directly.

MMP-2 is involved in the activity of other MMPs
Other members of the MMP family are also involved in vascular diseases.
At least 14 MMPs have been found in vascular cells. MMP-2 is involved in the
activation of MMP-9,65 which is another gelatinase in the MMP family and critical
for atherosclerosis and AAA formation in some animal models. MMP-2 also
facilitates MT-MMP to activate the zymogen form of MMP-13. There is evidence
that MMP-13 affects the development of atherosclerosis as well.127,99,161

MMP-2 influences LDL modification and VSMC contraction
More recently, it was reported that MMP-2 was involved in the modification
of LDL in arterial walls.203 Furthermore, MMP-2 promotes aortic dilation by
inhibiting the Ca2+ entry pathway of vascular smooth muscle contraction.27

V.

Potential

mechanisms

of

MMP-2

involvement

in

the

development of AAAs
Both secretion and activation of MMP-2 are augmented in human
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AAAs.74,141 MMP-2 deficient mice have been used to determine the role of MMP2 in AAAs. As mentioned above, abluminal application of CaCl2-induced AAA
formation was ablated in MMP-2 deficient mice.

MMP-2 is an elastiolytic enzyme
The hallmark pathology of AAAs is the progressive and irreversible
degeneration of the medial elastin lamellae. This destruction of elastin may
contribute to aneurysmal dilation and enlargement. Turnover of ECM plays a key
role in AAAs.8,122 As a major elastinase, MMP-2 is thought to be implicated in
AAA formation.

MMP-2 is involved in inflammatory cell adhesion and migration
Inflammatory cell recruitment and invasion are critical for the initiation and
progress of AAAs. A previous study by our lab, in hyperlipidemic mice,
demonstrated that the accumulation of macrophages in the media of aortic wall
after AngII-infusion is the earliest pathological event in AAA formation.172
Similarly, a clinical trial study demonstrated that the concentration of MMP-2 was
higher for small aneurysms as compared with large aneurysms, which suggests
that MMP-2 might contribute to early aneurysmal dilation.63 The potential role of
MMP-2 in the early stages of AAAs might encourage the development of new
approaches in the prevention of this disease.

Other potential roles MMP-2 might play in AAAs
MMP-2 may influence the apoptosis of vascular smooth muscle cells. The
apoptosis of VSMCs is a prominent feature of AAAs. A modification in the activity
of growth factors by MMP-2 might influence VSMC proliferation and apoptosis.
Intravascular thrombosis is one of the major pathological events of AAA. As
17

described above, MMP-2 potentiates the vWF effects on platelet adhesion
through up-regulating GPIb.

163

Therefore, MMP-2 might be involved in AAA

progression via influencing platelet aggregation and thrombus formation.
Other members of MMP family are also involved in AAAs. As mentioned
previously, MMP-2 is involved in the activation of MMP-9,65 which is another
member of the gelatinase sub-family and is critical for AAA formation in a couple
of mouse models.
The primary hypothesis of this research is that MMP-2 plays an important
role in the formation and progression of atherosclerosis and AAA in vitro and in
vivo. This hypothesis was tested in four specific aims: (1) to determine whether
MMP-2 deficiency is protective for atherosclerosis and angiotensin II-induced
AAAs in apoE-/- mice; (2) to investigate the phenotypic change in aortas of MMP2 deficient mice; (3) to investigate cell behavior of macrophages of MMP-2
deficient mice; (4) to determine whether bone marrow-derived MMP-2 is critical in
atherosclerosis and AAA formation in vivo. The data will be presented over four
chapters (Chapters 2-5) in this thesis.
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Figure 1.1 Classification of proteolytic enzymes
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Figure 1.2 Domain composition of MMP-2. Pre - signal peptide which is
removed after it directs synthesis to the endoplasmic reticulum; Pro – a propeptide with a zinc-binding SH group, which maintains enzyme latency until it is
removed or disrupted; II - Fibronectin type II repeats, which are cysteine-rich and
unique in MMP-2 and MMP-9; H - Hinge region; Zn - the catalytic domain
contains the conserved zinc-binding region.
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Figure 1.3 Activation of MMP-2 on the cell membrane MMP-2 has a unique
cell surface mode of activation in which it forms a ternary complex with MT1MMP (MMP-14) and TIMP-2. The N’ terminal of TIMP-2 binds the catalytic
domain of MT1-MMP, and the C’-terminal of TIMP-2 binds the hemopexin-like
domain of pro-MMP-2. The formations of this ternary complex makes pro-MMP2 localize at the cell surface and can be cleaved and activated by a TIMP-free
active MT1-MMP molecule, which localizes nearby. Therefore, TIMP-2, well
known as an endogenous inhibitor of MMP-2, is required for MMP-2 activation at
low concentrations. At high concentrations, TIMP-2 binds to N’-terminal of
activated MMP-2 and reduces the activity of the enzyme. Additionally, integrin
"v$3 is another molecule that may anchor proMMP-2 on the cell surface and
favor MMP-2 maturation. It was reported that MT1-MMP might activate "v$3
integrin through proteolytic cleavage.
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Chapter Two
The Effects of MMP-2 Deficiency on Atherosclerosis and AngIIInduced AAAs in Apolipoprotein E Deficient Mice
I. Background
Apolipoprotein E deficient mouse model of atherosclerosis
Atherosclerosis, a progressive disease, might be the most important
contributor to human mortality. Most studies of atherosclerosis in humans are
performed after the disease is highly developed, when clinical signs or symptoms
appear. In contrast, animal models permit investigators the opportunity to study
the initiation and progression of preclinical stages of this disease. In order to
provide essential information for treatment and prevention of the human disease,
animal models should closely mimic the histopathologic changes in human
disease as well as the interaction between pathogenetic factors and the disease
process. In past experiments involving atherosclerosis, rabbits were the preferred
model followed by non-human primates and swine. There are monetary
disadvantages associated with the acquirement and maintenance of these
animals, but more importantly, the scientific community is experiencing a moral
shift away from the use of higher mammals as research models. The advent of
the apoE deficient mouse model (referred to in this paper as apoE-/- or apoE
knockout), created by a targeted inactivation of the apoE gene, provides a
desirable research subject that is relatively cost effective for both experimental
and breeding purposes.160 Another hyperlipidemic model, LDL receptor deficient
(LDLr-/-) mice, can have modest increased plasma total cholesterol levels, and
require high fat diet to develop atherosclerosis. Because the pathology of
atherosclerosis in these mice is not as well characterized as apoE-/- mice, LDLr/- mice were not used in this dissertation project.
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ApoE is a 34kD glycoprotein important for lipid metabolism. It is a
component of all lipoprotein particles except low density lipoprotein (LDL). ApoE
is a high affinity ligand of the LDL receptor, and the chylomicron-remnant
receptor (LRP) on liver cells. Therefore, apoE is essential for the specific
uptaking of apoE-containing particles by the liver.221 ApoE also plays a key role
in stimulating macrophage cholesterol efflux.111 Although apoE -/- mice have
normal body weights and maturation, they tend to develop hyperlipidemia and
atherosclerosis spontaneously. To date, the apoE-/- mouse model is considered
to be one of the most common models in the analysis of atherosclerosis. The
atherosclerotic plaques of apoE-/- mice are extensive, reproducible and
demonstrate a close similarity to human atherosclerotic lesions. For instance,
lesions in both apoE-/- mice and humans have a tendency to progress from the
fatty streak stage to the fibrous plaque stage with obvious fibrous caps and
necrotic lipid cores. In addition to their histological similarities to humans, apoE-/mice also exhibit an exacerbation in atherosclerosis response to environmental
pathogenetic factors, such as smoking or a “western-type” diet, which contains
21% fat, 0.15% cholesterol, and no cholic acid.145, 185 However, it should be kept
in mind that apoE-/- mice have several features dissimilar to humans: lesions in
the aortic root of apoE-/- mice are foam cell-rich, rather than smooth muscle cellrich; plaque rupture is not observed in these mice whereas it occurs commonly
and leads to heart attacks in humans; and most cholesterol is carried in VLDL,
rather than in LDL as in humans.98,130

Despite some differences, the

atherosclerotic lesions formed in apoE-/- mice are remarkably similar to those
found in human disease. Therefore, of all available animal models, the apoE
deficient mouse has become widely used and accepted for research to identify
the role of cytokines, chemoattractants and intercellular adhesion molecules in
atherosclerosis.
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Mouse model of AngII-induced AAAs
There are several mouse-models of chemical-induced AAAs. One such
model uses the infusion of elastase into the infrarenal segments of mouse
aortas.162 A second model relies on periaortic administration of calcium chloride
between the renal branches and the iliac bifurcation.126 A more widely accepted
model applies chronic infusion of AngII to induce reproducible AAA formation and
accelerate atherosclerosis development in hyperlipidemic mice, including apoE-/and LDLr-/- mice. The AngII infused mouse model mimics several similar
features of AAAs in humans, such as a gender bias, luminal dilation,
inflammatory cell recruitment, elastin fiber degeneration, and thrombi formation in
AAA lesions. 126 There are two potential mechanisms by which AngII may induce
AAAs. First, AngII-infusion might stimulate inflammatory cell infiltration via
activating the NF-ĸB cascade and subsequently elevating certain cytokine levels,
such as MCP-1 and VCAM-1. Second, AngII-infusion might enhance the activity
of ECM degrading enzymes such as MMPs.130 Also, a previous study
demonstrated that the initial event in AngII-induced AAAs was the accumulation
of macrophages in the media of the suprarenal aorta. This event has been
associated with breaks in the elastin laminae, leading to thrombus formation and
atherosclerosis in apoE-/- mice.172

The role of AngII in cardiovascular diseases
The renin-angiotensin-aldosterone system (RAAS) is one of the most
critical in the regulation of hemodynamic homeostasis. When blood flow and
pressure are reduced in the renal artery, renin is secreted by the juxtaglomerular
apparatus (comprised of modified vascular smooth muscle of the afferent
arteriole) and released into the blood. Renin is a protease which cleaves the
inactive angiotensin I (AngI, 10 amino acid polypeptide) from a plasma protein
(angiotensinogen). As AngI passes through the capillaries of the lungs and other
organs, it is cleaved into AngII (an octapeptide) by angiotensin-converting

24

enzyme (ACE). Furthermore, AngII, which is the most biologically active
component of the RAAS, is cleaved into fragments by aminopeptidases. These
fragments of AngII include AngIII (2-8), AngIV (3-8) and some inactive fragments
(4-8, 5-8, and so on).131 In response to AngII and AngIII, the adrenal cortex
synthesizes and releases aldosterone, which increases sodium and water
retention by the collecting ducts, therefore, increasing blood volume and the
blood pressure. In addition, AngII, directly and indirectly, enhances tubular
reabsorption

of

sodium

in

proximal

tubules

as

a

consequence

of

glomerulotubular balance. AngII is a direct and potent vasoconstrictor of vascular
smooth muscle by activating Ca2+ channels and releasing Ca2+ from the
sarcoplasmic reticulum (SR).

151

Numerous clinical and laboratory data suggest

that the RAAS is involved in the pathogenesis of atherosclerosis. The
development of atherosclerosis in apoE-/- mice can be accelerated on a high fat
diet or by infusion of AngII.37 Multiple receptor subtypes exist for AngII including
AT1a, AT1b, and AT2. It is generally assumed that AngII transduces most of its
functions through AT1a receptors.146,38
AngII is not only implicated in hypertension, but also as a potent proinflammatory agent. In VSMCs, AngII is a potent stimulus for the generation of
ROS.77,
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In addition, AngII upregulates the expression of many cytokines

(including IL-1, IL-6, IL-8, MCP-1, TNF-alpha) and growth factors (including IGF,
TGF-beta, PDGF, bFGF) that have been implicated in the pathogenesis of
atherosclerosis. Furthermore, AngII induces production of adhesion molecules
(including osteopontin, VCAM-1, ICAM-1 and E-selectin).96,199 It was reported
that AngII enhanced the expression of integrin alpha v beta 3, and that blocking
antibodies to beta 3 attenuated AngII-induced adhesion in rat cardiac
fibroblasts.104 AngII induced leukocyte adhesion in both arterioles and venules
mediated by P-selectin and some other cell adhesion molecules. AngII increases
integrin beta 2 expression in peritoneal cells.11 When elevated, MCP-1 (an
important cytokine which is up-regulated by AngII) levels increased the CD11b
positive monocyte/macrophage population in circulating blood of mouse.197

25

AngII plays multiple roles in the regulation of MMPs. It was reported that
an antagonist of the AT1 receptor, irbesartan, reduced prostaglandin E2 (PGE2)dependent MMP-2 activity, and this effect may in turn contribute to
atherosclerotic plaque stabilization in humans.31 In cultured rat peritoneal
macrophages, an increased MMP-2 expression and activity can be elicited by
AngII and this increase was prevented by losartan, which is an antagonist of the
AT1 receptor.121 AngII, through several pathways, might elicit an increase of
MMP-2 activity indirectly. First, since the activity of pro-MMP-2 and pro-MMP-9 is
upregulated by ROS produced by macrophage-derived foam cells,164 AngII might
induce the activation of these MMPs through upregulating ROS production.
Second, it was reported that osteopontin deficiency led to a decreased activity of
both MMP-2 and MMP-9.20 This suggests that AngII may possibly increase MMP2 activation via up-regulating osteopontin. Third, TGF-beta is a MMP-2
upregulator. When there is an AngII-induced increase of TGF-beta, the event
may increase both expression and activation of MMP-2. Finally, it was reported
that AngII-induced MMP-2 release from endothelial cells is mediated by TNFalpha,7 as well as that AngII increases TIMP-1 in rat VSMCs.24
Taken together, one of the major and unique advantages of using mice for
experimental cardiovascular research is that it is possible to “knock out” or
replace endogenous genes, thereby determining the influence of protein
expression on the development of diseases. In this study, our hypothesis is that
MMP-2 deficiency might reduce atherosclerosis and AngII-induced AAA
development in an apoE deficient mouse model.

II. Materials and Methods
Animals
MMP-2 deficient mice (C57BL/6 background) were obtained from Dr.
Itohara (Brain Science Institute, RIKEN, Saitam, Japan). ApoE-/- mice on a
C57BL/6 background were obtained from the Jackson Laboratory (Bar Harbor,
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ME, USA). All of the mice were housed under barrier conditions with normal
laboratory diet and water ad libitum. MMP-2-/- mice and apoE-/- mice were then
bred and their offspring, generation F1 (MMP-2+/- x apoE+/-), were mated to
produce littermates with the desired MMP-2+/+ and MMP-2-/- x apoE-/- mice
genotypes (F2). Male MMP-2+/+, +/- and -/- x apoE-/- littermates were used in
all subsequent experiments. All procedures were performed with the approval of
the University of Kentucky Institutional Animal Care and Use Committee.

Experimental protocol
In order to address the issues raised by this specific aim, my experimental
protocol will be, primarily, two-fold. First, to investigate AngII-induced AAAs and
atherosclerosis in MMP-2+/+, +/-, and -/- x apoE-/-, I designed the experiment as
follows:

Second, I will use 20 to 24-week-old male apoE-/- mice with various MMP2 genotypes to investigate atherosclerosis development in aged hyperlipidemic
animals. These mice will be fed with normal laboratory diet and will not receive
AngII infusion.
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Polymerase chain reaction (PCR) for mouse genotyping
Genotyping for MMP-2 deficiency: PCR was performed using genomic
DNA isolated from tail snip samples of mice using a DNeasy tissue kit (Qiagen
Inc., Valencia, CA, USA). The exon1 of the MMP-2 gene was exchanged to
reverse pgk-neo gene in MMP-2-/- mice. The amplification was performed using
these specific primers: for the mutant allele, the forward primer recognized the
DNA

sequencing

on

the

reverse

pgk-neo

gene

(5'-

TGCAAAGCGCATGCTCCAGA-3'). The reverse primer recognized the DNA
sequence on exon2 (5'-TGTATGTGATCTGGTTCTTG-3'). The amplicon is 1.1Kb
(kilo-base pair) fragment. For the wild type allele, both primers recognize DNA
sequences

on

the

exon1

of

MMP-2.

CAACGATGGAGGCACGAGTG-3'

and

The

forward
the

primer

reads

reverse

5'5'-

GCCGGGGAACTTGATGATGG-3'. The amplicon is a 120bp (base pair)
fragment. The information for these primers was kindly provided by Dr. Itoh
(Institute for Virus Research, Kyoto, Japan). The thermocycling reactions were
performed as follows: 35 cycles of denaturation at 94°C for 1 minute, annealing at
57°C for 1 minute, extension at 72°C for 1 minute, followed by 1 cycle of final
elongation at 72°C for 7 minutes.
Genotyping for ApoE deficiency: To detect the apoE deficiency, PCR
was performed as described previously.160 The sequences of each primer were:
5'-GCCGCCCCGACTGCATCT-3'; 5'-TGTGACTTGGGAGCTCTGCAGC-3'; and
5'-GCCTAGCCGAGGGAGAGCCG-3'. Amplification of a single species of PCR
product of 245 bp (mutant allele) and/or 155 bp (wild type allele) corresponded to
a genotype. The thermocycling reactions were performed as follows: the initial
denaturation at 94°C for 1 minute, followed by 35 cycles of denaturation at 94°C
for 1 minute, annealing at 55°C for 1 minute, extension at 72°C for 1 minute, then
followed by 1 cycle of final elongation at 72 °C for 5 minutes.
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Gelatin zymography
Gelatin zymography was performed to confirm the disruption of the MMP2 gene as described previously.83 Frozen segments of mouse aorta were
homogenized in Rho-binding lysis buffer (RLB) containing Tris 50mM (pH7.2),
NaCl (150mM), MgCl2 (10mM), 1% Triton X-100, 0.1% SDS and 0.5% Sodium
deoxycholate for 30 minutes on ice. Following extraction, the homogenate was
centrifuged at 13,000 x g for 10 minutes at 4 °C. The protein content was
measured by a DC-protein assay kit (BioRad Lab., Hercules, CA, USA). A 7.5%
SDS-polyacrylamide gel containing 2% gelatin was pre-run at 50 volts for 5 to10
minutes. Protein extracts of aortas or lysis of mouse peritoneal macrophages
(MPMs) (15µg) and an appropriate amount of 5x non-reduced loading dye were
loaded onto the gel.

The gel was run at 50 volts until samples were through

stacking gel, then the voltage was increased to 120 volts. After the
electrophoresis, the gel was soaked in a 2.5% Triton X-100 solution for 1 hour at
room temperature (RT) on a shaker to remove SDS. Then the gel was washed
twice with distilled H2O (15 minutes per wash) at RT on a shaker. After washing,
the gel was incubated overnight at 37°C in 50 mM Tris buffer containing either 5
mM CaCl2 or 10 mM EDTA (negative control for MMP activity) on a shaker. Then
gel was stained with Brilliant Blue R (Sigma, St. Louis, MO, USA) for 15 to 30
minutes at RT. The gel was de-stained with 1x de-staining solution containing 1%
glycerol, 7.5% acetic acid, 30% methanol, and 61.5% H2O, until clear bands
appear. Bands of gelatin lysis by MMP-2 were quantified using a Kodak 440CF
image station.

AngII infusions and blood pressure measurement
For AngII infusion, mice were anesthetized with sterile saline containing
22.7% ketamine and 3.4% xylazine.

AngII (1,000 ng/kg/min) or saline was

administered subcutaneously via Alzet osmotic minipumps (DURECT Corp.,
Cupertino, CA, USA) as described previously.37
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Systolic blood pressures were obtained from conscious mice using a
computerized tail cuff method (BP-2000 Visitech Systems, Apex, NC,USA), as
previously described.38 Mice were acclimated to the system for two weeks prior
to the minipump implantation, and measurements were obtained at the same
time of day throughout the study, 5 days per week.

Peripheral white blood cell counting
Blood was obtained by retro-orbital bleeding of anaesthetized mice using
micro-hematocrit capillary tubes (Fisher scientific, Pittsburgh, PA, USA) and was
blown into microtainer tube with EDTA (Becton Dickinson & Co., Franklin Lakes,
NJ, USA). Peripheral blood cells were measured using a Coulter counter
(Beckman Coulter Inc. Miami, FL, USA).

Serum lipids and lipoprotein determination
Mouse serum total cholesterol concentrations were determined with
cholesterol enzymatic assay kits (Wako Chemical, Richmond, VA, USA). The
results were read on a 96-well plate with a microplate reader (Bio-Rad Model
550) at 490nm.
Lipoprotein cholesterol distributions were evaluated in individual serum
samples (50 µl) from 5 to 7 mice in each group after fractionation by size
exclusion chromatography on a single Superose 6 column.38 Fractions were
collected and cholesterol concentrations were determined with an enzymatic
based kit (Wako Chemicals USA Inc., VA, USA). The 96-well plates were read on
the microplate reader at 490nm.

Quantification of atherosclerosis
Quantification of lesions in aortic root sections: Atherosclerotic lesions
were quantified in the aortic root as described previously.40 In brief, the upper
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third portion of the heart was embedded and frozen in OCT (optimal cutting
temperature) compound (Sakura Finetec USA Inc., Torrance, CA, USA). The
heart was then sectioned on a cryostat from the direction of the apex toward the
aortic valves until the aortic valves or cusps were observed within the aortic
sinus. Beginning at this point, sections were cut at a thickness of 10 µm and
collected sequentially on eight slides, 9 sections on each slide. A total distance
of approximately 800 µm was taken for analysis.

Sections were stained for

neutral lipids using Oil Red O (Sigma), and counter stained with hematoxylin
(Biomeda corp., Foster City, CA, USA). Digital images were taken and lesions
were analyzed using ImagePro software version 4.1 (Media Cybernetics, Silver
Spring, MD, USA).
En Face quantification of atherosclerosis: The percentage of the
intimal area covered by atherosclerotic lesion was quantified in the aortic arch as
described previously.40 Aortas were fixed in 4% paraformaldehyde overnight.
After the periadventitial fat and connective tissue around aortas was removed,
aortas were cut and pinned on black paper placed over wax plates to expose the
intimal surface. Digital images were captured and atherosclerosis was measured
as a percentage of lesion area to total surface area using ImagePro software.

Classification of AAAs
AngII-induced AAAs were classified into four classes based on a standard
which is described previously.38 Type I AAA is defined as having a dilated lumen
in the supra-renal region of the aorta without thrombus. A Type II AAA is defined
as remodeled tissue in the supra-renal region that contains thrombus. Type III
AAA is defined as multiple aneurysms containing thrombus. The most severe
occurrence is a Type IV AAA and is defined as rupture that leads to death of
mouse (Figure 2.5).
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Immunohistochemistry staining
Air-dried cryostat (8µm thick) sections were fixed in cold acetone for 10
minutes, then were incubated with 1% hydrogen peroxide (H2O2) for 2-5 minutes
at 37°C, then were incubated in 5% blocking serum for 15-30 minutes, and with
respective antibodies: chicken anti-mouse MMP-2 (50µg/ml), MMP-14 (2.5µg/ml),
and TIMP-2 (10µg/ml) antibodies (Aves Labs, Inc., Tigard, OR, USA). Respective
pre-immune antibodies were used as negative controls. After washing, the
sections were incubated in biotinylated rabbit anti-chicken secondary antibody
(1:1,000; Jackson ImmunoResearch Lab Inc., West Grove, PA, USA).
For macrophage staining, a rabbit anti-mouse macrophage antibody (1:1,000;
Accurate Chemical & Scientific Corp., Westbury, NY, USA) was incubated for 15
minutes at 40°C, then incubated in biotinylated goat anti-rabbit secondary
antibodies (1:500; Vector Lab Inc., Burlingame, CA, USA). After washing, the
sections were incubated in Elite Vectastain ABC solution (Vector Lab. Inc.) for 10
minutes at 40°C, then washed with peroxidase enhancer buffer (Biomed Corp.),
then incubated with peroxidase chromogen (AEC; Biomed Corp.). After washing,
the slides were counter stained with hematoxylin and mounted with glycerol
gelatin (Sigma diagnostic Inc.).

Collagen staining using Gomori Trichrome
Sections (8 µm) of frozen tissue (aortic root) were fixed in cold acetone for
10 minutes and washed with distilled water. The slides were incubated with bouin
solution (a mixture of saturated picric acid (75 ml), 37-40% formaldehyde (25 ml),
and glacial acetic acid (5 ml)) for 1 hour at 56°C. After washing with dH2O until
yellow color disappears, the slides were incubated with working solution of
Weigert hematoxylin containing equal amounts of solution A (a mixture of
hematoxylin (0.5ml) and 95% alcohol (50 ml)) and solution B (a mixture of
concentrated hydrochloric acid (5 ml), 29% ferric chloride solution (20 ml), and
distilled H2O (47.5 ml)) for 10 min at RT. After rinsing with dH2O, the slides were
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incubated with Gimori solution for 15 to 20 minutes, then differentiated in 0.5%
acetic acid for 2 minutes at room temperature. After rinsing with ethanol, the
slides were rinsed again with water and mounted with permanent mounting
medium (H5000, Vector lab. Inc.).

Statistics
One-way ANOVA was performed to test the equality of three or more
means with one independent variable at one time by using variances. A
Student’s t-test was used to test the difference between two groups. All of the
statistical analyses were done with SigmaStat 2.03 software (SPSS Inc.,
Chicago, IL, USA). Values with P < 0.05 were considered statistically significant.

III. Results
Confirmation of the genotype of MMP-2 of mice
PCR was performed to examine the MMP-2 genotype of mice. The 1.1 kb
amplified DNA product of mutant allele was detected only in DNA from MMP-2-/mice and not in the DNA from MMP-2 wild type control mice (Figure 2.1 A).
Gelatin zymography of aortic extracts was performed to confirm MMP-2
genotypes of mice. As predicted, the band of gelatin lysis by MMP-2 was not
visualized in the extracts of aortas of MMP-2 deficient mice (Figure 2.1 B).

Effects of MMP-2 deficiency on AngII-induced AAAs and atherosclerosis in
hyperlipidemic mice
Effect on body and organ weight: MMP-2 -/- x apoE-/- mice showed a
tendency to have lower body weight when compared with MMP-2 +/+ x apoE-/mice before AngII infusion. However, there was not a statistically significant
difference (P = 0.082). After AngII-infusion for 28 days, a significantly lower body
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weight was observed in MMP-2 deficient mice as compared to MMP-2 wild type
mice (P < 0.05; Table 2.1). No significant difference was detected between the
body weight of MMP-2 +/- vs. either MMP-2 +/+ or -/- mice. There was a
correspondingly lower weight of the spleens from MMP-2-/- mice as compared
with spleens from MMP-2 +/- mice and MMP-2 +/+ mice at the end of the
experiment (P < 0.013; Table 2.1). However, the ratio of spleen to body weight of
these mice was similar. The livers of MMP-2-/- mice exhibited this trend as well,
however statistical significance was not achieved.
Effect on blood pressure: Mini-pumps filled with AngII were implanted
subcutaneously into mice. There was a significant increase of blood pressure
caused by AngII infusion in all of the three groups of mice with various genotypes
of MMP-2. However, no significant difference was detected among various MMP2 genotypes at both basal level and after AngII-infusion for 28 days (Table 2.1).
The increase of blood pressure level induced by AngII-infusion was similar in
each MMP-2 genotype mice group (MMP-2+/+ 33.5 ± 11.3 vs. +/- 43.0 ± 8.7 vs. /- 40.7 ± 2.6 mmHg).
The effect on serum cholesterol levels: Serum total cholesterol
concentrations were measured. There was a tendency of lower total cholesterol
(TC) level in MMP-2-/- mice compared with MMP-2 +/- and +/+ x apoE-/- mice (P
= 0.064; Table 2.1). Lipoprotein distribution was measured using size exclusion
chromatography. The curves of VLDL, LDL/IDL and HDL of mice with various
MMP-2 genotypes were overlapped with no significant difference (Figure 2.2).
The effect on atherosclerotic lesion area: The extent of atherosclerosis
was quantified with both en face analysis of the aortic arch and sequential cross
sectioning of the aortic root as described previously. Surprisingly, the area of
atherosclerotic lesion was similar among mice with various MMP-2 genotypes.
The percent atherosclerosis area on the intimal surface of aortic arch was 2.2 ±
0.5% vs. 3.9 ± 1.6% vs. 3.1 ± 0.8% in MMP-2-/-, +/- and +/+ x apoE-/- mice,
respectively (Figure 2.3). On the transverse sections of aortic root, the size of
atherosclerotic plaque was 12.9 ± 5.7 x 10-3 mm2 vs. 3.9 ± 1.1 x 10-3 mm2 vs.
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10.1 ± 3.8 x 10-3 mm2 in MMP-2-/-, +/- and +/+ x apoE-/- mice, respectively
(Figure 2.4).
The effect on AngII-induced aneurysms: AngII infusion (1,000
ng/kg/min) for 28 days generated AAAs in 50% of MMP-2 +/+ mice (3 out of 6),
67% of MMP-2 +/- mice (6 out of 9) and 67% of MMP-2 -/- mice (4 out of 6),
respectively (Figure 2.6). There was no statistical difference among the three
groups. Two of MMP-2+/- mice died of AAA rupture at the 6th and 23rd day of
AngII infusion, respectively. One MMP-2-/- mouse died of AAA rupture at the
nineteenth day of AngII infusion. No AAA rupture occurred in MMP-2+/+ mice.
Abdominal aortas were weighed to provide an index of AAA severity. The weight
of abdominal aortas was similar in each MMP-2 genotype mice group (19.7 ± 6.1
mg vs. 16.9 ± 3.3 mg vs. 18.2 ± 3.0 mg in MMP-2+/+, +/-, and -/- x apoE-/- mice,
respectively; Figure 2.7).

Effects of MMP-2 deficiency on atherosclerosis in 5 month-old ApoE-/- mice
General parameters: There was not a significant difference in the body,
liver or spleen weight among MMP-2+/+, MMP-2+/-, and MMP-2-/- x apoE-/mice. Interestingly, the number of peripheral white blood cell (WBC) was
dramatically raised in MMP-2-/- x apoE-/- mice as compared to MMP-2+/+ and
+/- x apoE-/- mice (Table 2.2).
The effect on atherosclerotic lesion area: The deficiency of MMP-2-/did not decrease the size of atherosclerosis in AngII-infused apoE-/- mice: No
protective effect from MMP-2 deficiency was detected concerning the size of
atherosclerotic lesions. Actually, the size of atherosclerotic plaque tended to
increase in MMP-2-/- apoE-/- mice (54.1 ± 20.5 x 10-3 mm2 vs. 11.0 ± 4.4 x10-3
mm2 vs. 18.5 ± 15.3 x 10-3 mm2 of the lesion area on the transverse sections of
aortic root in MMP-2-/-, +/-, and +/+, respectively; Figure 2.8). However, the
difference was not statistically significant. Interestingly, the deletion of the MMP-2
gene dramatically changed the cellular and ECM components of the
atherosclerotic plaques. The histopathologic and immunohistochemical staining
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demonstrated that collagen was increased as well as cellular content. Both
macrophages and smooth muscle cells were reduced in plaques of MMP-2-/mice as compared to plaques of MMP-2 wild type mice (Figure 2.9).
Immunostaining also indicated a relative reduction of MMP-14 and TIMP-2
expression in atherosclerotic lesion of MMP-2-/- x apoE-/- mice.

IV. Discussion
Twelve-week-old MMP-2-/- x apoE-/- mice showed lower body weight as
compared with MMP-2+/+ x apoE-/- mice. However, this difference in body
weight was not detected in 5-month-old apoE-/- mice. It was reported that the
inhibition of MMP-2 impairs adipose tissue growth via the formation of a collagenrich matrix cap in mice.123 On the basis of our data, we concluded that MMP-2
deficiency might retard but not ablate the development of adipose tissue of apoE/- mice. In future study, the weight of adipose tissue should be measured. MMP-2
deficiency did not influence AngII-induced hypertension in apoE-/- mice.
MMP-2 has been shown to degrade ECM components of the vascular wall
and become highly activated in AAAs and atherosclerotic lesions. It was reported
that MMP-2 deficient mice on a C57BL/6 background were resistant to CaCl2induced AAAs formation. 126 Thus, it was surprising that MMP-2 deficiency did not
reduce the size of atherosclerotic lesions or the incidence of AngII-induced AAAs
in apoE deficient mice. There are a few mechanisms that may account for this
discrepancy. First, MMP-2 might be insignificant in the progression of AAAs and
atherosclerosis and second, the increment of other pathogenic factors might
overwhelm the beneficial effect of MMP-2 deficiency in apoE-/- mice. Several
hypotheses might account for the latter mechanism.
MMP-2 deficiency might cause a compensatory over-expression of one or
more other elastinases in MMP-2-/- mice. As mentioned previously, MMP-9,
another member of gelatinase family, has been implicated in atherosclerosis and
AAAs. An adaptive mechanism might be activated in MMP-2 deficient mice, thus
increasing MMP-9 expression.
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Another reason may be that AngII infusion might enhance the production
of other elastinases. AngII is not only implicated in hypertension, but is also a
potent pro-inflammatory factor that has significant atherogenic actions via
multiple pathways. There are several mechanisms by which AngII may increase
the activity of MMP-9 in the vessel wall. AngII is a potent stimulus for the
generation of ROS,77,211 which upregulates MMP-9 activation in the vascular
wall.164 Also, AngII induces activation of MMP-9 via upregulating osteopontin,199
the deletion of which can cause a decrease in MMP-9 activity in apoE-/- mice.20
Finally, AngII induces production of many inflammatory cytokines. Some of these
cytokines, such as MCP-1, IL-1, TNF-alpha, may upregulate MMP-9 activity.30
AngII upregulates the expression of many growth factors including IGF,
TGF-beta, PDGF, and bFGF. These growth factors have been implicated in the
pathogenesis of atherosclerosis. Furthermore, AngII induces production of
adhesion molecules (including osteopontin, VCAM-1, ICAM-1 and E-selectin,
integrin alpha v beta 3, integrin beta 2).11,104,199 Elevated MCP-1, an important
cytokine that is upregulated by AngII, increases the CD11b positive
monocyte/macrophage population in mouse models.197
Hyperlipidemia might increase the activity of MMPs other than MMP-2.
There is plenty of evidence suggesting that lipid lowering by either lowcholesterol diet or lipid-lowering drugs leads to reduced activity of MMPs,
including MMP-9, reducing the extent of aortic dilation and increasing the stability
of

atherosclerotic

plaques

in

animal

models.

2,189

Furthermore,

the

hormone/cytokine-like anti-atherogenic effects of apoE on the surrounding cells
of the vascular wall should be considered in the current experiment in which
apoE null mice were used. It was realized that the anti-atherogenic roles of apoE
are beyond the regulation of lipoprotein metabolism and transport. Although the
mechanism is not completely understood, it was reported that apoE can
suppress the activation and proliferation of T lymphocytes via inhibiting important
signaling such as intracellular calcium accumulation and phosphatidylinositol
(PDI) turnover. 90 As a consequence, apoE inhibits the production of interleukin
(IL)-2.106 ApoE also inhibits SMC proliferation and migration via binding to
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LRP.223 Therefore, besides leading to hyperlipidemia in the mouse model, the
deficiency of apoE might exacerbate vascular diseases directly.
In summary, apoE deficiency and exogenous AngII might have synergetic
or additive pro-atherogenic effects on the atherosclerosis, overwhelming any
benefits the deletion of MMP-2 might create. Based on data from our non-AngII
treated MMP-2-/- x apoE-/- mice, we concluded that apoE deficiency might
negate any protective effects MMP-2 deficiency might provide in the initiation and
maturation of atherogenesis. Interestingly, the cellular and ECM content of the
atherosclerotic plaque were changed in MMP-2 deficient apoE-/- mice. This
suggested that the cell infiltration and ECM degradation during the pathologic
process of atherosclerosis were influenced by MMP-2 in spite of the possible
upregulation of the cytokines, growth factors, and other proteinases in the
vascular wall. The less pronounced immunohistochemical staining of TIMP-2
and MMP-14 might be due to the reduced cellular content in the plaques in MMP2-/- mice. Further study is required to quantify these changes and evaluate the
significance of the difference.
The current findings of this study make it essential to investigate the
phenotypic changes in the vascular wall and inflammatory cells of MMP-2
deficient mice. The hypothesis, concerning increased expression of other MMPs,
namely MMP-9, and the subsequent morphological changes in vascular wall and
associated inflammatory cells in the absence of MMP-2, will be presented and
evaluated in the next two chapters.
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Table 2.1 General parameters of AngII-infused 12-week-old male apoE-/- mice
with various MMP-2 genotypes
MMP-2+/+
x apoE-/-

MMP-2+/x apoE-/-

MMP-2-/x apoE-/-

Body weight before AngII
24.2 ± 0.9
infusion (g)

24.4 ± 0.5

21.1 ± 1.7

Body weight at the 28th
26.1 ± 0.6
day of AngII infusion (g)

25.7 ± 0.5

23.3 ± 1.1*

Body weight gain during
2.0 ± 0.6
AngII infusion (g)

1.3 ± 0.4

2.2 ± 0.8

Spleen weight (x10-2 g)

9.8 ± 0.3

9.9 ± 0.6

7.7 ± 0.5*

Liver weight (g)

1.26 ± 0.05

1.15 ± 0.07

1.03 ± 0.08

Spleen/body weight (%)

0.38 ± 0.02

0.38 ± 0.02

0.33 ± 0.01

Liver/body weight (%)

4.8 ± 0.1

4.5 ± 0.3

4.4 ± 0.3

Total cholesterol (mg/dl)

282 ± 12

230 ± 33

221 ± 12

124 ± 6

120 ± 4

167 ± 6†

161 ± 5†

Mouse

Blood pressure before
137 ± 10
AngII infusion (mmHg)
Blood pressure at the 28th
day of AngII infusion 159 ± 9†
(mmHg)

Data represent mean ± SEM for groups of 6-9 mice.
*P<0.05 with respect to MMP-2+/+ x apoE-/- mice
†
P<0.05 with respect to mice before AngII infusion
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Table 2.2 General parameters of 5-month-old male apoE-/- mice with various
MMP-2 genotypes
Mouse

MMP-2+/+
apoE-/-

x MMP-2+/apoE-/-

Body weight (g)

29.0 ± 1.0

30.6 ± 1.0

28.6 ± 0.7

Spleen
(x10-2 g)

10.2 ± 0.3

10.9 ± 1.5

14.8 ± 2.8

1.24 ± 0.08

1.24 ± 0.07

1.28 ± 0.06

7.1 ± 1.6

6.3 ± 0.6

13.1 ± 1.2*

weight

Liver weight (g)
WBC
cells/mm3)

(1x103

Data represent mean ± SEM for groups of 3-6 mice.
*P<0.05 with respect to MMP-2+/+ x apoE-/- mice.
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x MMP-2-/- x
apoE-/-

Figure 2.1 Confirmation of MMP-2 genotype of mice (A) Representive PCR
for MMP-2 genotyping is shown. The 1.1 kb band (for mutant allele) was
detected in DNA of MMP-2-/- mice and was completely absent in DNA of the wild
type control mice. The 120 bp band (for wild type MMP-2 allele) was detected in
DNA of wild type mice but not in DNA of MMP-2 -/- mice. (B) Gelatin zymography
of extracts (15µg) of aortas of MMP-2+/+ and -/- x apoE-/- mice. No MMP-2
expression was detected in MMP-2 deficient mice, whereas a prominent 72kDa
band of gelatin lysis by MMP-2 was present in the MMP-2 wild type mice.
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Figure 2.2 Effect of MMP-2 genotype and AngII infusion on the lipoprotein
distribution of 12-week-old apoE-/- mice Lipoprotein distribution of mice was
resolved using size exclusion chromatography, namely, fast performed lipid
chromatography (FPLC). The curves of VLDL, LDL/IDL and HDL of the mice
were overlapped. Points represent the means of 5-7 individual mice, and bars
are SEM.
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Figure 2.3 Effect of MMP-2 genotype on AngII-induced atherosclerosis on
aortic arch of 12-week-old apoE-/- mice The percentage of the intimal area
covered by atherosclerotic lesion was quantified in the aortic arch. The aortas
from mice that died from AAA rupture were not included. There was not a
significant difference in atherosclerosis among apoE-/- mice with various MMP-2
genotypes. Values obtained from individual mice are represented in open
symbols, the means are depicted as closed symbols and SEM as bars.
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Figure 2.4 Effect of MMP-2 genotype on AngII-induced atherosclerosis on
aortic root of 12-week-old apoE-/- mice
Area of atherosclerosis was
measured in the sections of aortic root of mice. Lesion area was determined in
10 µm-thick sections at 80 µm intervals after Oil Red O staining. Values obtained
from individual mice are represented in open symbols, the means are depicted
as closed symbols and SEM as bars.
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Figure 2.5 Classification of AngII-induced AAAs. Type I AAAs is defined as
dilated lumen in the supra-renal region of the aorta without thrombus. Type II
AAAs is defined as remodeled tissue in the supra-renal region that contains
thrombus. Type III AAAs is defined as multiple aneurysms containing thrombus.
Type IV AAAs is defined as rupture of AAAs which led to death of mouse.
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Figure 2.6 Effect of MMP-2 genotype on the incidence of AngII-induced
aneurysms in 12-week-old apoE-/- mice Incidence of AAA in mice from each
group (n=6-9/group). No significant difference was detected among mice with
various MMP-2 genotypes.
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Figure 2.7 Effect of MMP-2 genotype on the severity of AngII-induced
aneurysms in 12-week-old apoE-/- mice Abdominal aortas were isolated by
cutting the aorta at the level of the diaphragm and the iliac bifurcation. The tissue
was weighed to provide an index of AAA severity. No significant difference was
detected among mice with various MMP-2 genotypes. Values obtained from
individual mice are represented in open symbols, the means are shown as
closed symbols and SEM as bars. These data do not include the tissue weight of
three mice (two MMP-2+/- mice and one MMP-2-/- mouse) that died from AAA
rupture during AngII infusion.
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Figure 2.8 Effect of MMP-2 genotype on atherosclerosis in 5-month-old
apoE-/-mice
Area of atherosclerosis was measured in the sections of aortic
root of 5-month-old male mice. Lesion area was determined in 10 µm-thick
sections at 80 µm intervals after Oil Red O staining. Values obtained from
individual mice are represented in open symbols, the means are depicted as
closed symbols and SEM as bars.
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Figure 2.9 Histopathological and immunohistochemical pictures of
atherosclerotic lesion on aortic root of 5-month-old apoE-/- mice Crosssections of the aortic root of 5-month-old male MMP-2+/+ x apoE-/- (A, C, E, G, I,
K) and MMP-2-/- x apoE-/- (B, D, F, H, J, L) mice were stained with Oil Red O
staining (A and B; 40x), Gomori trichrome staining (C and D; blue-collagen; redsmooth muscle cells).
The sequential sections were used to do
immunohistochemical staining for macrophages (E) and (F), MMP-2 (G) and (H),
MMP-14 (I) and (J), and TIMP-2 (K) and (L). C-F and I-L: the detail of boxed area
in the Oil Red O staining in A and B on sequential sections (200 x); Bars indicate
50 µm.

49

Chapter Three
Phenotypic Changes in MMP-2 Deficient Mice
I. Background
Genetically engineered mice are widely used in the functional analysis of
the genes involved in cardiovascular diseases. These mice provide ideal
approaches to study the members of gene families that encode several
isoenzymes and lack selective inhibitors and inducers. For example, the
influence of MMPs in genetically modified mice was investigated in studies as
mentioned previously (in Chapter 1). Despite the high level of specificity,
sometimes genetic engineering leads to unexpected results. Some of these
results may provide insight into new functions of genes, which have not been
detected or anticipated based on previous pharmacological interventions.
Frequently, transgenic animals do not show obvious phenotypic changes.
The normality of the animal might be due to the insignificance of the gene.
However, this normality may also be due to the activation of an adaptive
mechanism that effectively compensates for the loss of that specific gene.
Therefore, a detailed functional and morphological analysis of the transgenic
animal is considered an important issue for the correct evaluation of the gene. It
should be kept in mind that in contrast to a pharmacological approach, which
usually causes an acute intervention with too little time for an adaptive
mechanism, a transgenic approach is more like a chronic intervention allowing
the animal time to develop possible compensatory adaptations. 72

MMP-2 gene mutation in humans
In humans, homoallelic MMP-2 mutation on chromosome 16q12-q22
causes a loss of all three MMP-2 functional domains: the Zn2+ binding site
catalytic domain, the three fibronectin type II-like domains and the hemopexin
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domain. Consequently, MMP-2 activity is completely ablated. MMP-2 ablation is
assumed to alleviate the bone absorption in arthritis since MMP-2 is assumed to
be a pivotal enzyme for bone and extracellular matrix turnover. However, the
paradox in affected individuals is that the absence of MMP-2 leads to an
autosomal recessive disease that is characterized by an excessive reabsorption
and destruction of bones and arthritis. The patients have a set of ‘vanishing bone
syndromes’, in which the bones, primarily the bones of hands and feet, are
severely reabsorbed and destructed. The patients also have chronic arthritis and
subcutaneous nodules in the hands and feet. The underlying mechanism is
unclear. There are a couple of hypotheses for the findings in these patients –
1)there might be compensatory overproduction of other protease(s) in patients
with MMP-2 gene mutant or 2) MMP-2 might be essential for processing of the
inductive factor which is required for the activity of osteoblasts or the regulation
of the activity of osteoclasts.134, 188

MMP-2 gene deficiency in the mouse model
MMP-2 deficient mice were developed in 1998 for use in cancer research.
It was soon discovered that MMP-2

reduced angiogenesis and tumor

progression in these animals.97 Although some morphological changes (including
a mild growth retardation and delayed mammary gland development) were
evident, these mice were not known to mimic the human disease found in bones
and joints.188 It was consistently reported that the inhibition of MMP-2 impairs
adipose tissue growth via the formation of a collagen-rich matrix cap in mice.123
Other phenotypic changes of MMP-2 deficient mice include: 1) a decreased
allergen inhaling-induced lung inflammatory cell egression which increases
susceptibility to asphyxiation,35
outgrowth, corneal angiogenesis,

2) a significant reduction of endothelial
103

and extra-retinal neo-vascularization in

oxygen-induced retinopathy,150 and 3) an early onset and severe experimental
autoimmune encephalomyelitis due to an increase in MMP-9 expression and
activity.53
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MMP-2 deficient mice were used in research of cardiovascular diseases
as well. Some related findings conclude that targeted deletion of MMP-2
attenuates cardiac rupture after experimental myocardial infarction

80,136

reduces intimal hyperplasia in blood flow cessation in the carotid arteries.

and

101,114

As mentioned previously in this dissertation, MMP-2 null mice are resistant to
CaCl2-induced AAAs.126 However, there is a shortage of literature investigating
characteristics of the vascular wall and inflammatory cells of MMP-2 deficient
mice. Such an investigation is essential for an in-depth understanding of the role
of MMP-2 in cardiovascular diseases. The surprising result we have obtained in
our previous study (in Chapter 2) makes this investigation an even more
important event. The genotypic characteristics of several MMP deficient mice are
listed in Table 3.1.

II. Materials and Methods
Animals
Six-week-old male mice on C57BL/6 background were obtained from The
National Cancer Institute (NCI, Frederick, MD, USA). They were used as control
mice to detect the morphological change in aortic wall of MMP-2 deficient mice.
MMP-2 deficient mice (C57BL/6 background) were obtained from Dr. Itohara
(Brain Science Institute, RIKEN, Saitam, Japan).
ApoE-/- mice on a C57BL/6 background were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). MMP-2-/- mice and apoE-/- mice were then
bred and their offspring, generation F1 (MMP-2+/- x apoE+/-), were mated to
produce littermates with the desired MMP-2+/+ and MMP-2-/- x apoE-/- mice
genotypes (F2). Male MMP-2+/+ and -/- x apoE-/- littermates were used in all
subsequent experiments. All of the mice were housed under barrier conditions
with normal laboratory diet and water ad libitum. All procedures were performed
with the approval of the University of Kentucky Institutional Animal Care and Use
Committee.

52

Elastin staining using Verhoeff’s iron hematoxylin
Age and gender-matched MMP-2 -/- and wild type mice on C57BL/6
background were sacrificed and infused with 4% paraformaldehyde via the left
ventricle at stable pressure (approximate 100 mmHg) for 60 to 90 minutes.
Fragments from the abdominal aorta directly above the renal artery branch were
cut and frozen in O.C.T. compound. Sections (8 µm) of frozen aortas were
stained in Verhoeff’s iron hematoxylin (a mixture of 5% hematoxylin in absolute
alcohol (20 ml), 10% Ferric chloride (8 ml) and Verhoeff’s iodine (8 ml)) for 20
minutes. Sections were differentiated in 2% ferric chloride. When the nuclei and
elastin fibers were still black, and the background was weakly stained, the
staining was halted. The sections were washed in distilled water, then in 95%
alcohol to remove the iodine coloration. The slides were rinsed in distilled water
again and mounted with glycerol gelatin.

Mouse peritoneal macrophage harvest
Age and gender-matched MMP-2 -/- and wild type mice on C57BL/6
background were anesthetized with sterile saline containing 22.7% ketamine
3.4% xylazine, then a cervical dislocation were performed. A slit was made in the
outer skin in order to provide a “window” of visibility to the peritoneum. Sterile
saline (5 ml) was injected into the peritoneal cavity through the intact abdominal
musculature then slowly withdrawn through the same syringe needle. Fluid and
cells were transferred into a 15 ml conical tube on ice. After centrifuging at 1,000
x rpm for 5 minutes at RT, the supernatant was discarded. If there were RBCs
visually detectable, 5ml of red blood cell (RBC) lysing solution containing 0.83%
ammonium chloride and 0.158% Tris HCl (Sigma) was added into the tube. After
2 to 5 minutes, cells were spun down at 1,000 x rpm for 5 minutes. The
supernatant was discarded. The cells were lysed again if RBCs were still
present. After lysis, RIPA buffer (100 ml) containing 1% NP-40, 0.5% sodium
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deoxycholate, 0.1% SDS, 0.001% aprotinin, 1mM sodium orthovanadate, and
0.01% PMSF (phenylmethyl sulfonyl fluoride) was added into each tube. The
cells were incubated for 30 minutes on ice then transferred into microfuge tubes.
The tubes were centrifuged at 13,000 x g for 10 minutes at 4°C. The supernatant
was collected, and stored at -20°C. The protein content was measured using a
micro BCA protein assay kit (Pierce, Rockford, IL, USA).

Gelatin zymography
Age and gender-matched MMP-2-/- x apoE-/- and MMP-2+/+ x apoE-/mice were sacrificed. Frozen aortas (from aortic arch to the iliac bifurcation) were
homogenized. Gelatin zymography was performed as described previously in
Chapter 2.

In this study, we compared the expression of MMP-9 in aortic

extracts of these mice. Age and gender-matched MMP-2 -/- and wild type mice
on C57BL/6 background were sacrificed and peritoneal macrophages were
isolated as described above. Gelatin zymography was performed to compare the
expression of MMP-9 in peritoneal macrophages. The MMP-9 level in aorta
extracts of these mice was measured as well.

Peripheral white blood cell counting
Age and gender-matched MMP-2 -/- and wild type mice on C57BL/6
background were sacrificed. The experiment was performed as described
previously (in Chapter 2).

Statistics
Student’s t-test was used to test the difference between two groups. All of
the statistical analyses as above were done by a SigmaStat 2.03 software.
Values with P < 0.05 were considered statistically significant.
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III. Results
MMP-2-/- mice have lower body weights
Age-matched male MMP-2 deficient mice have a lower body weight as
compared to MMP-2 wild type mice (n = 7/group; P < 0.01). Corresponding to the
lower body weight, the weight of the spleens, livers and hearts of MMP-2 -/- mice
were lower as well. However, no difference was detected in the heart/body
weight and liver/body weight ratios of MMP-2+/+ and -/- mice (Table 3.2). We
also observed that MMP-2 deficient mice have flatter faces and noses (Figure
3.1), as well as shorter tails than their wild type counterparts. Although MMP-2 is
involved in ovulation, the reproductive ability of MMP-2 mice appears normal (810 pups per litter).

MMP-2-/- mice have a higher peripheral WBC count
Blood was collected from mice (n = 10 -11/group). The MMP-2 genotype
did not create any significant differences in the number of red blood cell,
platelets, or concentration of hemoglobin. Interestingly, the number of WBC was
dramatically raised in MMP-2-/- mice (12.2 ± 1.5 x 103 cell/mm3) when compared
with MMP-2+/+ mice (6.5 ± 0.6 x 103 cell/mm3; P < 0.05; Figure 3.2).

MMP-2-/- mice have increased branching of the elastin fibers in the
abdominal region of the aorta
Sections of abdominal aorta from six-month-old wild type and MMP-2-/male mice were stained with Verhoeff’s iron hematoxylin (n = 9-10/group).
Branches of elastin fibers in the aortic walls were counted. An increased level of
branching was observed in aortas from MMP-2-/- mice compared with aortas
from MMP-2+/+ mice. (19.44 ± 1.07/section vs. 6.9 ± 1.13 per section; P < 0.05;
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Figure 3.3)

MMP-2-/- x apoE-/- mice have increased MMP-9 levels in aortic extracts
Gelatin zymography of aortic extracts from age and gender matched
MMP-2+/+ and MMP-2-/- x apoE-/- mice was performed. The average band
intensity from gelatin lysis by MMP-9 was increased 143% in the extracts of
aortas of MMP-2 deficient mice compared with the aortas of MMP-2 +/+ (P <
0.01; Figure 3.4). We also sought to determine the MMP-9 level in MMP-2-/- and
MMP-2+/+ mice on a C57BL/6 background (apoE+/+). However, the expression
of MMP-9 in these aortas was too low to be detected by gelatin zymography
(data not shown).

MMP-9 expression tends to increase in MMP-2-/- peritoneal macrophages
Gelatin zymography of peritoneal macrophage extracts from age-matched
male MMP-2 wild type and MMP-2 deficient mice was performed. The average
intensity of bands of gelatin lysis by MMP-9 was increased 98% in the extracts of
aortas of MMP-2 deficient mice compared with aortas of MMP-2 wild type mice.
However, there was no statistical significance (P = 0.2; Figure 3.5).

IV. Discussion
MMP-2 null mice show some phenotypic differences when compared to
their MMP-2 wild type counterparts, although these differences are less dramatic
than those associated with MMP-14 null mice, which have severe bone and
connective tissue abnormalities, inadequate collagen turnover and early
postnatal death 85 (Table 3.1).
In our current study, we observed that MMP-2 deficient mice have lower
body weight, flatter faces (noses) and shorter tails than their MMP-2 wild type
counterparts. This might be due to a mild abnormality in the development of
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connective tissues, such as bone, cartilage, and adipose tissue.

We were

surprised to observe that MMP-2 deficient mice exhibited a similar size of
atherosclerotic lesion and a similar incidence of AngII-induced AAA in a
hyperlipidemic mouse model (see Chapter 2). Therefore, we did several
experiments to determine the underlying mechanisms.
We confirmed the genotype of MMP-2 deficiency in the knockout mice by
gelatin zymography.

The ablation of the MMP-2 phenotype allowed us to

concentrate on the peripheral pathways. We measured blood pressure to
examine the hemodynamic conditions present in the MMP-2 deficient mouse.
Pressures for both knockout and control mice under both basal conditions and
AngII infusion were consistent with previous findings. We then compared the
aortic wall structure of MMP-2 -/- and +/+ mice. Interestingly, we observed an
increased number of branches in elastin fibers of the aorta of MMP-2 null mice
compared with aorta of wild type mice. This may provide protection from AAAs by
strengthening the vascular wall. It also may signal the destruction and
remodeling of ECM, and increased rigidity of vascular wall. Future study is
required to measure the vascular contractility of MMP-2-/- mice.
MMP-2-/- x apoE-/- mice consistently expressed elevated levels of MMP-9
in aortic tissue extracts as compared to wild type controls, as determined by
gelatin zymography. However, in aortas of MMP-2-/- mice on a C57BL/6 wild
type background (apoE+/+) and MMP-2 wild type control mice, the MMP-9 level
was too low to be detected by gelatin zymography (data not shown). This
indicates

that

hyperlipidemia

might

be

involved

in

the

compensatory

overexpression of MMP-9 in apoE-/- mice. Another potential mechanism
underlying this compensation is that MMP-2 might be required to regulate the
expression and/or activation of other elastinases. Recently, it was reported that
the MT1-MMP/TIMP-2/MMP-2 complex, in addition to facilitating the activation of
pro-MMP-2, could be involved in regulating the expression of MMP-9 in
lymphocytes of mice.53 MMP-2 deficient mice showed a tendency to have higher
MMP-9 expression in peritoneal macrophages as compared to wild type control
mice. However, there was not a statistical significance.
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In addition, we detected a significant increase in peripheral white blood
cell (WBC) number in MMP-2 null mice. Infection, leukemia and tissue damage
are the three most common reasons for a high WBC count and secondary
immunodeficiency. However, splenomegaly, which is an important sign of
infection, is not observed in MMP-2 deficient mice. One study has been
published that studied the role of MMP-2 expression in clinical course of acute
myeloid leukemia (AML). It surprisingly showed that 82% of the MMP-2 positive
patients survived for over 3 years, whereas all MMP-2 negative patients relapsed
within 13.5 months of diagnosis.113 Compared to solid tumors, this finding is
surprising, as increased MMP-2 expression in solid tumors is often related with a
more biological aggressive and invasive phenotype.41,81,142 However, the role of
MMPs in increased angiogenesis and leukemic cell growth have not been
extensively investigated. Further studies need to be completed to determine the
mechanism underlying the high peripheral WBC number of MMP-2 null mice.
Our studies identified phenotypic changes in the aortic vessel wall and
peripheral white blood cells of MMP-2 null mice. Many of these changes are
currently unexplained and further investigation may bring insight into the broader
biological role of MMP-2. These data support that MMP-2 plays a complex role
beyond degradation of ECM in vascular diseases.
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Table 3.1 Phenotypes of transgenic mice lacking MMP-2, MMP-9, MMP-14 and
TIMP-2 genes
Gene
deficiency

Phenotypes

MMP-2

Mild growth retardation and delayed mammary gland
development 190
reduced intimal hyperplasia in a mouse carotid artery
blood flow cessation model 101,114
Reduced

AAA

formation

induced

by

abluminal

10

application of calcium chloride in mice
MMP-9

Resistant to aneurysms induced by elastinase infusion
and abluminal application of CaCl210,162
Prolonged contact dermatitis199
Defective osteoclast recruitment 52

MMP-14

Reduced collagen turnover
Impaired endochondral ossification and angiogenesis;
Death before the onset of sexual maturity83,222
Severe

postnatal

growth-retardation

abnormalities212
TIMP-2

Deficient MMP-2 activation212
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and

skeletal

Table 3.2 Body and organ weight of 6-week-old male MMP-2+/+ and -/- mice
Mouse

MMP-2 +/+

MMP-2 -/-

Body weight (g)

22.4 ± 0.6

18.4 ± 0.9*

Spleen weight (x10-2 g)

7.9 ± 0.3

6.7 ± 0.5*

Spleen/body weight (%)

0.35 ± 0.01

0.36 ± 0.02

Liver weight (g)

1.30 ± 0.04

0.98 ± 0.10*

Liver/body weight (%)

5.8 ± 0.2

5.3 ± 0.4

Data represent mean ± SEM for groups of 7 mice.
*P<0.05 with respect to MMP-2 +/+ mice
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Figure 3.1 Craniofacial differences between MMP-2 +/+ and MMP-2 -/- mice.
Representative pictures of a MMP-2+/+ and -/- mouse were taken while subjects
were anaesthetized. The MMP-2 deficient mouse (on the right) has a depressed
face and shorter nose than the MMP-2 wild type mouse.
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Figure 3.2 Peripheral WBC counts from MMP-2 -/- and MMP-2 +/+ mice.
Blood was obtained by retro-orbital bleeding and the cells were counted using a
Coulter counter (n=10-11/group). Histobars represent the means and bars are
SEM. (*P < 0.01 for comparisons of MMP-2 deficient mice versus wild type mice)
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C

Figure 3.3 Morphological changes in the aortic wall of MMP-2 -/- and MMP-2
+/+ mice (A and B) Representative sections of elastin staining using Verhoeff’s
iron hematoxylin of abdominal aortas from six-month-old male MMP-2+/+ and -/-.
Arrows indicate branches of elastin fibers. (C) The number of elastin fiber
branches counted in each section. Values obtained from individual mice are
represented as open circles, means are depicted as closed diamonds and SEM
as bars. (n = 9-10/group; *P < 0.05 for comparisons of MMP2+/+ versus -/- mice)
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A

B

Figure 3.4 Aortic extract expression of MMP-9 in MMP-2-/- and MMP-2+/+ x
apoE-/- mice. (A) Gelatin zymography of protein extracts from mouse aortas.
(B) Gelatinase activity was quantified by densitometry. Data were obtained from
3 individual mice. Histobars represent the means and bars are SEM. (*P < 0.05
for comparison of MMP-2 deficient versus MMP-2 wild type aortas)
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A

B

Figure 3.5 Mouse peritoneal macrophage expression of MMP-9 in MMP-2 -/and MMP-2 +/+ x apoE-/- mice. (A) Gelatin zymography of protein extracts of
macrophages. Protein extracts (15µg in each line) from aortas of MMP-2 wild
type or MMP-2 deficient apoE-/- mice. (B) Gelatinase activity was quantified by
densitometry. Data were obtained from 4 individual mice. However, there was not
a statistical significance (P = 0.2). Histobars represent the means and bars are
SEM.
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Chapter Four
Reduced Adhesion Ability and Integrin Beta 3 Expression in
MMP-2 Deficient Macrophages (in vitro)
I. Background
The recruitment of inflammatory cells from the circulation and their transendothelial migration into the vascular wall are prominent features in both
atherosclerosis and AAAs. There are considerable new insights into the
mechanism underlying the recruitment of inflammatory cells. The initiating step of
this process might be the random contact of inflammatory cells to the
endothelium,

followed

by

cell-rolling,

-tethering,

-arresting,

and

cell-

transmigrating through the endothelium. Adhesion molecules/receptors, including
selectins, immunoglobin-like molecules (such as ICAM, VCAM, and PECAM),
cadherins, and integrins are involved in this process. 68, 93, 94
As mentioned previously, many types of cells in the vascular wall including
endothelial cells, VSMCs, and fibroblasts, produce MMP-2 constitutively.
Inflammatory cells, such as macrophages, T lymphocytes, and mast cells,
produce MMP-2 as well. Unlike the mesenchymal cells, inflammatory cells
produce MMP-2 in a relative small amount.

During the occurrence of

inflammation, including vascular diseases, pathophysiological changes might
modify the production of MMP-2 by inflammatory cells. For instance, secretion of
MMP-2 by T lymphocytes can be upregulated by an interaction between the cell
and fibronectin through alpha 4 beta 1 integrins, as well as a ligation of VCAM1.216 The expression of macrophage-derived MMP-2, which is not as abundant
as macrophage-derived MMP-9, was significantly reduced in CCR-2 deficient
mice.153 In cultured rat peritoneal macrophages, an increased MMP-2 expression
and activity can be elicited by AngII and subsequently prevented by losartan, an
AT1 receptor antagonist.121 As mentioned in Chapter 1, most MMPs are secreted
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as zymogens and are not activated spontaneously. It is thought that MMPs
secreted by macrophages could serve as activators of MMPs derived from other
cell types, including VSMCs.147

The potential role of MMP-2 in the regulation of macrophage behavior and
cell-matrix interaction
MMP-2 activity might influence the behavior of inflammatory cells, playing
a pivotal role in cardiovascular diseases. There is evidence that MMP-2 is able to
facilitate neutrophil-endothelial cell adhesion by cleaving pro-endothelin into an
active form in vitro.
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Furthermore, it was reported that degradation fragments of

ECM components, generated by the action of MMP-2, are involved in
macrophage migration in a myocardial infarction mouse model.136 As mentioned
in Chapter 1, ECM proteins may bind to cytokine receptors, growth factor
receptors and cell-adhesion receptors thus transducing receptor-mediated
signalings, which are important for regulating biological functions of the cell,
including mobility, proliferation, and apoptosis. Meanwhile, the binding of ECM
proteins may influence cell behavior by influencing the binding of other ligands to
these receptors.
Integrins are the major receptors mediating cell-to-ECM and cell-to-cell
adhesion. They have been studied extensively, becoming the most-understood
cell adhesion receptors.47 The integrin family is comprised of 24 members. Each
member is categorized as a heterodimeric transmembrane glycoprotein,
containing one of 18 alpha and one of 8 beta subunits. Differentiation is achieved
by the unique, non-covalent coupling of these subunits. Integrins mediate cell
adhesion by activating a variety of protein tyrosine kinases like focal adhesion
kinase (FAK) and Src-family kinases. Integrins also initiate intracellular signaling
molecules which control cell shape, migration, proliferation, differentiation and
survival.68 In adherent cells, integrins are apparently in a constitutively active
form which is induced by inside-out signaling events such as Rho-like GTPase,
certain cations (e.g. Mn2+), and antibodies (Figure 4.1). This ligand binding at the
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cytoplasmic domain of integrins changes their conformation from inactive to
active form by splitting away the alpha subunit, which allows the interaction of
beta subunit with the cyto-skeletal components. In the active conformation, the
affinity of integrin and its ligands is enhanced, therefore, the outside-in signaling
pathway can be turned on and modulate cell behaviors.

36,48,88

Although the

mechanism underlying the regulation of integrin-mediated cell adhesion is
unclear, it is clear that integrin-mediated cell spreading leads to increased
adhesion.
Cell migration is a process that also requires the strict regulation of
integrin-mediated adhesion and release of the adhesive cell. A net movement of
the cell is due to the cooperation of two elements: 1) the repeated cycle of the
assembly and disassembly of adhesive complexes which leads to the protrusion
of the cell membrane at the front part and 2) the cyto-skeletal contraction and
detachment of the cell rear part. There is evidence that a pool of integrins is
internalized and recycled to the rear part of the cell, demonstrated by rearligand-bound integrins left behind on the surface of substrate.

17,155,168

Furthermore, the interaction between integrins might affect cell migration and
surface expression levels of these molecules, causing a “clustering” of integrins,
which may influence the affinity of both integrins and their ligands.205 The
interactions between integrins and receptor kinases such as the EGF and the
PDGF receptors have also been reported. These interactions could lead to the
clustering of growth factor receptors, thereby enhancing the downstreamsignalings.60
Like other integrins, integrin alpha v beta 3, is involved in cell adhesion,
migration and survival.19,175,204 As mentioned in Chapter 1, alpha v beta 3 integrin
also functions as an anchor protein of MMP-2 on the cell surface, becoming
involved in MMP-2 activation. Integrin alpha v beta 3 is expressed by many cell
types,

including

macrophages,

endothelial,

smooth

muscle,

fibroblasts,

osteoclasts, and others.133 It associates with a variety of ECM proteins such as
vitronectin, osteopontin, fibronectin, fibrinogen, thrombospondin, proteolysed
collagen, and von Willebrand factor. It also associates with some important cell
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surface

molecules

including

MMP-14,

MMP-2,

VEGFR2,

IAP,

and

CD47.46,82,86,187,212 The expression of integrin alpha v beta 3 on endothelial cells
was found to increase when nitric oxide (NO) levels were increased in rat cardiac
fibroblasts. Related to this, the blocking antibodies to beta 3 attenuated AngIIinduced adhesion in rat cardiac fibroblasts.104,116 Another study reported that
blocking integrin alpha v beta 3 inhibits macrophage adhesion and migration.214
Pharmacological blockade of the integrin alpha v beta 3 inhibits angiogenesis in
cancer and rheumatoid arthritis patients.23 Furthermore, an organic molecule
(TSRI265) which selectively blocks integrin alpha v beta 3 interaction with MMP2 without influencing MMP-2 activity, inhibits angiogenesis and tumor growth in
nude mice.19,184 It was also reported that alpha v beta 3 integrin regulated
macrophage foam cell formation, possibly influencing the progression of
atherosclerosis in humans.6
In this study, we sought to investigate the influence of MMP-2 deficiency
on certain cell behaviors found in mouse peritoneal macrophages. We also
sought to examine the potential effects of the interaction between MMP-2 and
integrin alpha v beta 3 on macrophage behavior.

II. Materials and Methods
Adhesion assay of peritoneal macrophages
Peritoneal macrophages were collected from six to eight-week-old MMP2+/+ and MMP-2-/- male mice as described previously (see Chapter 3) and
plated (4 x 105 cells/well) in collagen I-coated 24-well plates (Becton Dickinson,
Bedford, MA, USA). Cells were incubated in serum free DMEM media (800
µl/well) at 37 oC for 30 minutes in a humidified incubator containing 95% air and
5% CO2. The MPMs were then washed 3 times with serum free DMEM media.
Attached cells were either stained with hematoxylin for cell counting, or
harvested and lysed to measure the protein content using a micro BCA protein
assay kit as described previously (Chapter 3). Cell counting was performed using
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ImagePro software. Six independent fields from each well (5 wells for each
group) were analyzed using a light microscope at a magnification of 100X.
For controls, peritoneal macrophages from 6-week-old C57BL/6 mice
were harvested and incubated with 10µM TSRI265 (Calbiochem, San Diego, CA)
in DMEM containing 10% serum replacement (heat-treated bovine albumin and
insulin, without MMP-2 and 9; Sigma) at 37 oC for 3 hours in a humidified
incubator containing 95% air and 5% CO2. This compound is a known disruptor
of MMP-2 binding to integrin alpha v beta 3 without influencing MMP-2 activation.
After three washings with serum free media, the cells were harvested and lysed
for protein content, measured using a micro BCA protein assay kit as described
previously.

Invasion assay of peritoneal macrophages
Peritoneal macrophages were collected from six to eight-week-old wild
type mice as described previously (Chapter 3). A twenty four-well matrigel
invasion chamber (BD Biosciences, San Diego, CA, USA) was used. The upper
chambers contained a matrigel layer and a microporous filter (8 µm pore
diameter). Either no serum or 10% FBS in DMEM 750µl was added in the bottom
chambers. Macrophages (4 x 105/well) were seeded on the upper chamber in
500µl οf DMEM

containing 10% serum replacement either with or without

TSRI265 (10µM) and incubated at 37 oC for 18 hours in a humidified incubator
containing 95% air and 5% CO2. The cells that migrated to the lower chamber
were fixed and stained with hematoxylin and counted as described above.

RT-PCR
mRNA was isolated from peritoneal macrophages using a mRNA isolation
kit (Promega, Madison, WI, USA). The primer sequences of integrin beta 3 are:
forward

5’-GGGGACTGCCTGTGTGACTC-3

and

reverse

5’

CTTTTCGGTCGTGGATGGTG-3’.15 The conditions of the cycling reactions are
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as follows: 40 cycles of denaturation at 94°C for 30 seconds, annealing at 58.1°C
for 1minute, extension at 68°C for 2 minutes, followed by 1 cycle of elongation at
68°C for 2 minutes. The mRNA signals of beta actin were used as loading
controls.

The

primer

sequences

of

beta

actin

are:

forward

5'-

GAGACCTTCAACACCCC-3' and reverse 5'-GTGGTGGTGAAGCTGTAG-3'.39
The conditions of cycling reactions are: 40 cycles of denaturation at 94°C for 30
seconds, annealing at 60°C for 1minute, extension at 68°C for 2 minutes,
followed by 1 cycle of elongation at 68°C for 2 minutes.

Immunofluorescence staining for integrin beta3 (CD61) in MPMs
Peritoneal macrophages of MMP-2 deficient and wild type mice were
cultured in an 8-well Lab-Tek chamber slide (0.3 x 106/well) in serum free DMEM
for 3 hours. The media was deleted and the cells were fixed in cold acetone for
10 minutes. After fixation, the cells were washed twice with 1x PBS. Cells were
incubated with 15% goat serum for 3 hours at room temperature or overnight at
4º C to block the non-specific reaction, then incubated with purified hamster antimouse CD61 (integrin beta3) antibody (1: 20; 2C9.G2; BD Pharmingen, San
Diego, CA, USA) overnight at 4°C. After washing 5 times with 1x PBS, the cells
were incubated with Alexa Fluor 488 conjugated goat anti-hamster secondary
antibody (1: 500; A-21110; Molecular Probes, Eugene, OR, USA) for 30 minutes
at RT. The cells were washed 8 times with 1xPBS. The genomic nuclei were
counterstained with Hoechst 33258 (1µg/ml) for 5-10 minutes. The chamber was
removed. The slides were mounted with gel/mount (Catalog number M01,
Biomed, Foster City, CA, USA). Images were captured digitally by a fluorescence
microscope (Nikon eclipse E600, Japan) with exposure times kept constant.

Flow cytometry of integrin beta 3 for MPMs
Mouse peritoneal macrophages (1x106 cells/ml/ FACS tube) were
incubated with purified rat anti-mouse CD16/CD32 monoclonal antibody (1:100,
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30µl/0.02µg/106 cells; BD Pharmingen) in 1mM EDTA containing Hank’s media
or 1xPBS/0.5% BSA for 15-30 minutes at 4°C. This reduces the Fc receptormediated binding by antibodies of interest. The cells were incubated with RPhycoerythrin (R-PE)-conjugated rat anti-mouse CD11b (1:20, 2µl/0.02µg/106
cells) and fluorescein isothiocyanate (FITC)-conjugated hamster anti-mouse
CD61 (2µl /1µg/106 cells) monoclonal antibody (BD Pharmingen) for 30 minutes
on a rocker at 4°C. Cells were then centrifuged at 1,000x rpm for 5 minutes at 4°
C and the supernatant aspirated. After washing twice with 2.0 ml washing buffer
(1xPBS/0.5% BSA), the cells were re-suspended in 250µl sterile FACS tubes
with 1 x PBS solution. Immunofluorescence was analyzed with a flow cytometer.

Statistics
Data are presented as means ± SEM. One-way ANOVA was performed to
test the equality of three or more means with one independent variable at one
time by using variances. Student’s t-test was used to test the difference between
two groups. All of the statistical analyses above were done with SigmaStat 2.03
software. P values < 0.05 were considered statistically significant.

III. Results
Disruption in the binding of MMP-2 to integrin alpha v beta 3 reduces
peritoneal macrophage invasion but not adhesion
We sought to determine the influence of the interaction between MMP-2
and integrin alpha v beta 3 mouse peritoneal macrophages on the certain cell
behavior, particularly adhesion and invasion. Application of TSRI265, a disruptor
of MMP-2 binding to integrin alpha v beta 3, led to a 53 percent reduction in
macrophage invasion through matrigel when compared to the non-treated cells
(P < 0.01; Figure 4.2). The lower chambers, containing serum free media, were
used as controls. The protein amounts from attached cells were also measured
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after incubating with TSRI265 (10µM) for 3 hours and washing. However, no
significant change in cell adhesion was detected (P = 0.106; Figure 4.3).

Peritoneal macrophages from MMP-2 -/- mice have reduced adhesion
activity
In this experiment, we sought to examine the migration activity of
peritoneal macrophages of MMP-2 deficient mice. The cell adhesion assay was
performed. We observed a reduction in cell migration that might be due to the
reduced adhesion ability of MMP-2 deficient macrophages.

Peritoneal

macrophages were collected from eight-week-old male MMP-2+/+ and -/- mice
(n = 3-5/group). After culturing (30 minutes) and washing, the attached cell
number of MMP-2-/- macrophages was significantly less compared to the cell
number of wild type macrophages (51.8 ± 16.3/well vs.770.2 ± 126.5/well; P <
0.001). To confirm this data, after washing, the attached cells were collected and
lysed. The protein content of the cell lysate was measured. Correspondingly, we
observed that the protein concentration from the cell lysate of MMP-2 deficient
macrophages was 57% lower than the protein concentration from wild type
macrophage cultures (P < 0.001). The experiment was repeated without culturing
or washing, and the protein content of wild type and MMP-2-/- macrophages was
found to be similar (Figure 4.4).

Peritoneal macrophages from MMP-2 -/- mice have reduced integrin beta 3
expression
We

measured

integrin

beta3

expression

in

mouse

peritoneal

macrophages with RT-PCR and immunofluorescence staining. These techniques
demonstrated that the mRNA level of integrin beta 3 was reduced by 58% in
peritoneal

macrophages

of

MMP-2-/-

mice

(P

<

0.05;

Figure

4.5).

Immunofluorescence staining and flow cytometry demonstrated a significant
reduction of integrin beta 3 expression in MMP-2 deficient peritoneal

73

macrophages as well (P < 0.05; Figure 4.6; 4.7). These data suggest that the
reduced adhesion, which was observed in MMP-2 deficient macrophages, might
be due to the reduced expression of integrin beta 3, but not be due to the
absence of interaction between these two proteins.

IV. Discussion
The

recruitment

of

macrophages

is

a

common

and

prominent

characteristic of both AAA and atherosclerotic tissue. In these diseases, the
invasion of macrophages and release of cytokines and proteolytic enzymes are
critical in the initiation and progression of vascular remodeling. Cell adhesion is
the initial step in the trans-mural infiltration of macrophages. Integrins are the
pivotal receptors that mediate cell-to-ECM and cell-to-cell adhesion. In particular,
integrin alpha v beta 3 facilitates the activation of MMP-2 by localizing pro-MMP2 on the cell surface.
There is evidence that the expression and activation of integrin alpha v
beta 3 can not only correlate with other cell types, such as invasive tumor cells,
but also correlate with the activation of MMP-2 and MMP-14.26,184 The binding
ability of MMP-2 to integrin alpha v beta 3 is independent of the pathway that
activates MMP-2. A disruption of this mechanism has been shown to inhibit
angiogenesis and tumor growth, however, the details of the mechanism has not
been elucidated.107,184

Another study suggests that the disruption of MMP-2

binding to integrin alpha v beta 3 inhibits the invasion of mouse peritoneal
macrophages.214 In addition to data concerning the outcome in the inhibition of
MMP-2/integrin v beta 3 binding, a recent study demonstrated that the beta3
antagonist m7E3 (abciximab) reduced the activity of MMP-2 and MMP-9 as well
as smooth muscle cell migration in rats.10
A currently accepted model of integrin mediated cell migration is that a
ligand or signaling induced by another agonist might bind to the cytoplasmic
domain of the alpha-subunit and induce a conformational change by splitting the
cytoplasmic domains of the alpha and beta subunits. In the inactive form, the
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alpha-subunit inhibits the interaction between the beta-subunit and the
cytoskeletal components. Consequently, this inhibition can be removed by ligand
binding. The rate of binding between integrins and ligands is increased during
integrin clustering. Intrinsically, the binding to ligands with multiple binding sites
or by cytoskeletal interactions may lead to the clustering of integrins.

88,207

Subsequently, the integrins associate with alpha-actinin, leading to a stable
interaction with the cytoskeleton.171
As mentioned previously, integrins are in a constitutively active
conformation in adherent cells. Our findings indicate that MMP-2, as a ligand of
integrin alpha v beta 3, might influence macrophage behaviors indirectly through
the expression of integrin beta3 or directly by interacting with integrin alpha v
beta 3. Chapter 1 discussed the importance of many studies that demonstrated
MMP-2 facilitated cell migration through a cleaving the ECM. However, there are
controversial opinions about the role of MMP-2 in cell adhesion.57,167,217 This
discrepancy may be due to the various ECM and cell types used, but most likely
is linked to the limited understanding of the processes and mechanisms
influencing adhesion turnover in migrating cells. It was reported that MMP-2
influences neutrophil-endothelial adhesion by cleaving the latent endothelin-1
(ET-1) to the potent ET-1 in vitro.58,59 Mouse macrophages express MMP-2 in a
relative small amount as compared to MMP-9 (Figure 3.5). However, in the
present study, we demonstrated for the first time that MMP-2 deficiency reduced
adhesion activity of mouse peritoneal macrophages. This reduction in adhesion
might be due to a reduction in integrin beta 3 expression.
Future studies are required to determine the influence of MMP-2 on other
adhesion molecules, such as selectins, VCAM, ICAM, and other integrins. Also,
more experiments are required to determine the role of MMP-2 in the regulation
of other cell behaviors such as survival and apoptosis as well.
Although the exact mechanism underlying the reduced integrin beta 3
expression on MMP-2 deficient macrophages is unknown, several hypotheses
may account for this observation. First, MMP-2 might upregulate integrin
expression by influencing the activity of certain growth factors. As mentioned
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previously (in Chapter 1), MMP-2 can modify the activity of many growth factors
through multiple pathways. For example, MMP-2 facilitates the release of TGFbeta by degrading the collagen-associated proteoglycan decorin, which is an
anchor protein of TGF- beta. MMP-2 can proteolytically cleave and activate latent
TGF-beta as well. Since TGF-beta is able to upregulate the expression of
integrins,220 MMP-2 might upregulate integrin expression via increasing TGFbeta activity. Moreover, MMP-2 may decrease the activity of basic fibroblast
growth factor (bFGF) by cleaving the FGF receptor-1. There are controversial
opinions for the role of bFGF in the expression of integrin alpha v beta 3 in
microvascular endothelial cells. Klein et al. reported that bFGF decreased alpha
v beta 3 expression.
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On the contrary, Sepp et al. demonstrated that bFGF

increased alpha v beta 3 integrin expression.

179

It is reported that recombinant

VEGF is able to upregulate integrin alpha v beta 3 expression in human
microvascular endothelial cells.178 However, there is not evidence that VEGF
activity can be influenced by MMP-2. Taken together, the reduced integrin beta 3
expression on MMP-2 deficiency macrophage might be due to the loss of local
MMP-2 control on growth factors, especially, TGF-beta and bFGF. Another
potential mechanism is based on the evidence that the expression of integrins
can be controlled by the interactions between cells and their surrounding ECM.44
The degradation of the ECM by MMP-2 might influence the integrin expression of
cells. Other leukocytes, especially T lymphocytes, play important roles in
vascular diseases. In this study, we did not determine the influence of MMP-2 on
other types of inflammatory cells. Future studies are required to test these
hypotheses.
We detected a tendency of enhanced production of MMP-9 in mouse
peritoneal macrophages of MMP-2 deficient mice. This discovery is supported by
recent evidence showing a 10-fold increase in the inactive form of MMP-9 in
macrophages by gene transfection did not reduce the rupture of atherosclerotic
plaques in carotid arteries of mice (Gough P. presented in the 6th annual
conference on Atherosclerosis, Thrombosis and Vascular Biology, 2005).
Although MMP-9 can be activated by several serine proteinases, it was reported
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that proMMP-9 activation was accomplished by the active forms of MMP-2.
These forms are generated after the activation of TIMP-2-free proMMP-2 on the
surface of cancer cells. Regarding that study, we concluded that MMP-2 might be
important in the regulation of macrophage behaviors by interacting with integrin
alpha v beta 3. Therefore, MMP-2 is involved in cell adhesion and invasion
through multiple pathways, not just its ability to digest the ECM.
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B

Figure 4.1 Pathways outlining the influence of integrin alpha v beta 3 on
cell behaviors. Integrins mediate cell adhesion to ECM and to other cells
through activating a variety of protein tyrosine kinases like focal adhesion kinase
(FAK) and Src-family kinases. Integrins also initiate intracellular signaling
molecules that control cell shape, adhesion, migration, proliferation,
differentiation and survival. In adherent cells, integrins are apparently in a
constitutively active confirmation. Interaction between integrins and receptor
kinases (RTKs) affects cell migration and surface expression levels of integrins.

78

Figure 4.2 The influence of MMP-2 and integrin alpha v beta 3 interaction
on macrophage invasion Numbers of macrophages invading through matrigel
in the presence of no serum,10% FBS, or 10% FBS with TSRI265 (n = 4 wells
per group). Histobars represent the means and bars are SEM. *P < 0.01 for
comparisons of TSRI265 treated versus untreated MPMs; #P < 0.01 for
comparisons of wells with FBS versus wells without FBS
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Figure 4.3 Disruption of MMP-2 binding to integrin alpha v beta 3 did not
influence macrophage adhesion. BCA protein assay for macrophages shows
attachment to the plate after 3 hours incubation either with or without TSRI265
10µM and washing (n = 6 wells per group) Histobars represent the means and
bars are SEM.
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A

B

Figure 4.4 Reduced adhesion activity of MMP-2 deficient macrophages
(A) After 30 minutes culturing and washing, the macrophages attached in the
plate were counted. (n = 5 wells per group) (B) BCA protein assay for the
macrophages attached in the plate after 30 minutes incubation and washing (n =
3-5 wells per group; *P < 0.001 for comparisons of MMP-2 wild type versus
MMP-2 deficient macrophages) Histobars represent the means and bars are
SEM.
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Figure 4.5 RT-PCR of integrin beta 3 expression in MMP-2 deficient
macrophages. RT-PCR was performed to semi-quantify the integrin beta3
mRNA from macrophages of MMP-2 wild type and deficient mice. The expected
amplicons for integrin beta3 were less pronounced in MMP-2 deficient
macrophages compared with MMP-2 wild type macrophages. Beta actin mRNA
signals were used as loading controls.
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Figure 4.6 Immunofluorescence staining of integrin beta 3 expression in
MMP-2 deficient macrophages. Immunofluorescence staining for integrin beta
3 on macrophages was performed. Staining was much less pronounced in
macrophages of MMP-2 deficient mice (B) as compared with macrophages of
MMP-2 wild type mice (A). Hoechst nuclear staining was performed in the same
field of A (C) and B (D), respectively.
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Figure 4.7 Flow cytometry of integrin beta 3 expression in MMP-2 deficient
macrophages. The percentage of integrin beta 3 expression positive peritoneal
macrophages was reduced in MMP-2-/- mice compared to wild type mice (n =
4/group; P < 0.05).

84

Chapter Five

The Effects of MMP-2 Deficiency in Bone Marrow-Derived
Cells on AngII-Induced AAAs and Atherosclerosis
in ApoE-/- Mice (in vivo)
I. Background
There are two common features in the pathogenesis and evolution of
abdominal

aortic

aneurysms

(AAAs)

and

atherosclerosis:

infiltration

of

inflammatory cells (especially macrophages and lymphocytes) into the vascular
wall and remodeling of the extracellular matrix (ECM) at the site of
inflammation.63,170 These two pathologic processes collaborate to form a vicious
cycle in the progression of vascular diseases. Proteases and cytokines are
enhanced by infiltrative macrophages, and this elaboration accelerates ECM
degeneration; vice versa, the degradation of ECM components facilitates the
infiltration of inflammatory cells into the vascular wall and leads to an elaboration
of proteases and cytokines in situ.49,157 Therefore, proteases and cytokines might
serve the primary linkage of this cycle.
As a protease, MMP-2 (gelatinase A) is involved in cell-to-cell and cell-tomatrix interactions in many physiological and pathological processes such as
wound healing, cancer metastasis, and inflammatory joint diseases. MMP-2 first
attracted attention in cardiovascular diseases primarily because of its ability to
digest a diverse array of ECM components (including elastin and collagen) of the
vascular wall. Furthermore, it was reported that MMP-2 facilitated neutrophilendothelial cell adhesion through cleaving pro-endothelin into an active form in
vitro.58 Our previous study (in Chapter 4) demonstrated that macrophage-derived
MMP-2 regulates macrophage adhesion and invasion through interacting with
integrin alpha v beta 3. All of the above suggests that MMP-2 is not only involved
in the remodeling of the ECM via the proteolysis of ECM components, but also
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may be implicated in the infiltration of inflammatory cells into the vessel wall by
modulating cell behaviors.
The bone marrow transplantation technique provided a useful approach to
examine the contribution of hematopoietic cell gene expression to diseases.
Bone marrow transplantation in the apoE-/- and LDLr-/- mouse models has been
well established as a method for examining the effect of protein expression by
inflammatory cells on the development of cardiovascular diseases. The
repopulation of peripheral blood leukocytes by the transplanted bone marrowderived cells can be confirmed.

14,124

It was also reported that the lethally

irradiated mice without bone marrow transplantation died within 14 days after the
irradiation.162
In this study, we addressed the hypothesis that the MMP-2 produced by
bone marrow-derived cells might play an important role in AngII-induced vascular
diseases in vivo. MMP-2 gene targeted mice were used to achieve this purpose
as bone marrow donors.

II. Materials and Methods
Animals
MMP-2-/- mice and apoE-/- mice were mated and bred. F1 (MMP-2+/- x
apoE+/-) mice were mated to produce littermates of MMP-2+/+ x apoE-/- and
MMP-2-/- x apoE-/- mice (F2). Six- week-old male MMP-2+/+ and MMP-2-/- x
apoE-/- littermates were used as bone marrow donors. These mice were
genotyped by PCR as described previously (in Chapter 2). Six-week-old male
apoE-/- mice were used as bone marrow-derived cell recipients.

Experimental protocol
The experiment was designed as follows:
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Bone marrow-derived cell transplantation
One week prior to irradiation and bone marrow transplantation, mice were
given prophylactic treatment with the antibiotic sulfatrim (4 mg/ml) via their
drinking water. ApoE-/- recipient mice were irradiated with 900 rads from a
cesium γ source, given as a single dose. Bone marrow was harvested from the
femurs and tibias of MMP-2-/- and their littermate MMP-2+/+ x apoE-/- (n =
4/group) mice by flushing with Hank’s buffered saline solution (1 ml). Cells were
washed, re-suspended, and counted. Irradiated recipient apoE-/- mice (n = 1417/group) were injected intravenously via the tail vein with 7 x 106 bone marrow
cells from donor mice. The mice were maintained on antibiotic water for four
weeks following irradiation. After an interval of 6 weeks to permit hematopoietic
engraftment, the study was initiated.
All of the following experiments were performed as described in Chapter 2:
PCR (polymerase chain reaction) for mouse genotyping
AngII infusion and blood pressure measurement
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Peripheral white blood cell counting
Serum lipids and lipoprotein determination
Quantification of atherosclerosis
Classification of AAAs

Statistics
Data are presented as means ± SEM. Two-way ANOVA (two factor
analysis of variance) was performed to analyze experiments with two
independent variables (i.e. AngII treatment and genotype of MMP-2). One-way
ANOVA was performed to test the equality of three or more means with one
independent variable at one time by using variances. Student’s t-test was used to
test the difference between two groups. All of the statistical analyses as above
were done by a SigmaStat 2.03 software (SPSS Inc.). A repeating ANOVA was
performed to analyze the data of the systolic blood pressure of the mice using a
SAS software. Fisher exact probability test was used to determine differences
between groups in the incidence of aneurysm formation. Values with P < 0.05
were considered statistically significant.

III. Results
Repopulation of irradiated apoE-/- mice with MMP-2+/+ or MMP-2-/- bone
marrow-derived cells
Gelatin zymography of aortic extracts was performed to confirm genotypes
of the donor mice. As predicted, the band of gelatin lysis by MMP-2 was not
visualized in the extracts of aortas of MMP-2 deficient mice. The bone marrow of
the recipient mice was harvested at the time of sacrifice and genotyped by PCR.
The 1.1 kb amplified DNA product of mutant allele was detected only in bone
marrow derived cell DNA from MMP-2-/- bone marrow recipient mice, but not in
the DNA from MMP-2+/+ bone marrow transplanted control mice. This suggests
that the transplanted bone marrow cells successfully repopulated the bone
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marrow of recipient mice (Figure 5.1).

Effect of bone marrow transplantation and AngII infusion on blood
composition of the recipient mice
Blood was collected via retro-orbital bleeding and analyzed (n = 9 -11
mice were chosen randomly for each group) one day before the termination of
the experiment (Table 5.1). MMP-2 genotypes of the bone marrow-derived cells
did not lead to a significant difference in the number of white blood cell (WBC),
red blood cell (RBC), hemoglobin (Hb) or platelet. AngII infusion did not change
peripheral blood WBC and platelet count. Interestingly, AngII infusion caused a
significant rise in the number of RBC and a corresponding increase in Hb level
for both MMP-2 deficient and MMP-2 wild type bone marrow cell recipient mice
(P < 0.001).

Effect of bone marrow transplantation and AngII infusion on the body
weight of the recipient mice
The recipient mice did not gain body weight as normal mice due to the
irradiation (Figure 5.2; n = 14 -16/group). There was a significant loss of body
weight in AngII infused mice compared with saline infused mice (-2.2 ± 0.3 g vs.
1.3 ± 0.3 g; P < 0.001). However, there was no statistical difference between
MMP-2+/+ and -/- bone marrow-derived cell recipient mice (P = 0.499).

Effect of bone marrow transplantation and AngII infusion on the blood
pressure of the recipient mice
Systolic blood pressure was measured in conscious mice using a
computerized non-invasive tail-cuff system, 5 days per week (n = 10 -11/group).
Saline infusion did not change systolic blood pressure of the recipient mice. AngII
infusion increased systolic blood pressure in both MMP-2+/+ and -/- bone
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marrow-derived cell recipient mice (P < 0.0001). There was a significant change
of blood pressure caused by the interaction between AngII infusion and time
within the AngII treated mice (P < 0.001; Figure 5.3). Neither MMP-2 genotype in
bone marrow cells caused significant differences in blood pressure.

Effect of bone marrow transplantation and AngII infusion on the cholesterol
profile of the recipient mice
The genotype of MMP-2 of bone marrow-derived cells and AngII infusion
did not cause statistically significant difference in total serum cholesterol
concentrations (TC). For MMP-2+/+ bone marrow recipients, the TC was 183 ±
12 mg/dl in saline group vs. 204 ± 20 mg/dl in AngII group; for MMP-2-/- bone
marrow recipients, the TC was 161 ± 6 mg/dl in saline group vs. 190 ± 21 mg/dl
in AngII group. There was a mild increase of TC in AngII infused mice (n = 9 10/group; P = 0.138; Figure 5.4). No significant difference was detected in
lipoprotein distribution in MMP-2+/+ and MMP-2-/- bone marrow transplanted
mice (Figure 5.5).

Effect of bone marrow transplantation on AngII-induced hypertrophy of the
aortic arch of the recipient mice
AngII infusion induced significant hypertrophy in the aortic arches of
recipient mice. The aortic arch area was increased significantly in AngII-infused
mice as compared to saline-infused mice (P < 0.001). However, MMP-2
deficiency in bone marrow derived cells did not ablate the hypertrophy (Figure
5.6; n = 10-11/group; P = 0.728). For saline infused mice, the area of aortic arch
was 16.0 ± 0.7 mm2 in MMP-2+/+ bone marrow-derived cell recipients vs. 16.0 ±
0.5 mm2 in MMP-2-/- bone marrow-derived cell recipients. For AngII treated mice,
the area of aortic arch was 21.7 ± 0.8 mm2 in MMP-2+/+ bone marrow cell
recipients vs. 21.2 ± 0.7 mm2 in MMP-2-/- bone marrow cell recipients.
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The repopulation of MMP-2-/- bone marrow-derived cells significantly
decreased the atherosclerosis formation in the recipient mice
The extent of atherosclerosis was quantified both by en face analysis of
the aortic arch and thoracic aorta (Figure 5.7 and 5.8) and sequential cross
sectioning of the aortic root (Figure 5.9). Both methods demonstrated a
significant reduction of AngII-induced atherosclerosis in MMP-2-/- bone marrow
cell-repopulated mice as compared to MMP-2+/+ bone marrow cell-repopulated
mice (2.1 ± 0.2% vs. 5.7 ± 0.6% of thoracic aorta and aortic arch area, P < 0.001;
7.2 ± 2.5 x 10-3 mm2 vs. 24.5 ± 6.7 x 10-3 mm2 of the lesion area on the
transverse sections of aortic root, P < 0.05). Saline-infused MMP-2-/- bone
marrow transplanted mice demonstrated a tendency toward reduction of
atherosclerosis compared to wild type bone marrow recipient mice (0.2 ± 0.0%
vs. 0.7 ± 0.2% of thoracic aorta and aortic arch area; 2.9 ± 1.0 x 10-3 mm2 vs. 8.2
± 2.5 x 10-3 mm2 of plaque area on the transverse sections of aortic root).
However, this was not statistically significant.

The repopulation of MMP-2-/- bone marrow-derived cells prevented the
AngII-induced AAA formation in the recipient mice
Abdominal aortic aneurysms were not detected in saline-infused recipient
mice. AngII infusion (1,000 ng/kg/min) generated AAAs in 53% (nine out of
seventeen) of mice with MMP-2+/+ bone marrow derived cells and 12.5% (two
out of sixteen) of mice with MMP-2-/- bone marrow derived cells (n = 14 17/group; P < 0.05; Figure 5.11). There was no statistical difference between
saline and AngII infused MMP-2-/- bone marrow derived cell recipients (P =
0.30). AAAs were classified into four classes based on the standard that was
described in Chapter 2. Both AAAs occurred in MMP-2-/- bone marrow cell
recipient mice were type II AAAs. Among MMP-2+/+ bone marrow recipient mice,
one type I, five type II, and one type III AAAs developed. In addition, two MMP2+/+ bone marrow-derived cell recipient mice died from AAA rupture, which is
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defined as type IV AAAs, at the 8th and 10th day of AngII infusion, respectively
(Figure 5.11). Abdominal aortas were weighed to provide an index of AAA
severity. In saline-infused mice, MMP-2 deficiency in bone marrow-derived cells
did not influence the weight of the abdominal aorta of mice. However, abdominal
aorta weight increased markedly after AngII infusion compared with saline
infusion (P < 0.001). This increase was significantly attenuated in MMP-2-/- bone
marrow-derived cell transplanted mice. The weight of abdominal aorta was 23.2
± 2.1 mg in MMP-2+/+ bone marrow-derived cell recipients vs. 16.8 ± 1.2 mg in
MMP-2-/- bone marrow-derived cell recipients (n = 14 -16/group, P < 0.05; Figure
5.12).

IV. Discussion
In this study, our major finding is that MMP-2 deficiency in bone marrowderived cells decreased the incidence of AngII-induced AAA and the severity of
atherosclerosis in apoE-/- mice. Linked with the reduced invasion ability of
peritoneal macrophage of MMP-2 deficient mice, this result is rational. The
immunohistochemical staining for macrophage indicated a reduction of
macrophage content in atherosclerotic plaques of MMP-2-/- bone marrow cell
recipient mice. However, this might be due to the reduced plaque size in these
mice (Figure 5.10). Further study is required to quantify the reduction and
evaluate the significance of the difference.
The apoE-/- mouse model is considered to be the most useful model for
atherosclerosis analysis because of its high histological similarity to human
diseases. In this model, macrophages are the major cellular component of the
atherosclerotic plaque. At the age of 5 to 6-weeks, apoE-/- mice demonstrated
monocytic adhesion and trans-endothelial migration to the endothelial surface of
the aorta, detected by electron microscopy (EM). At 6 to 10-week-old, most
apoE-/- mice have developed fatty-streak lesions comprised primarily of foam
cells with a small number of migrating smooth muscle cells. These fatty-streak
lesions rapidly progress to advanced lesions, which are typically comprised of a
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necrotic core surrounded by proliferating smooth muscle cells and varying
amounts of ECM, including collagen and elastin.145 In AngII-induced AAAs, the
infiltration of macrophage into the vascular wall is a predominant feature also
found in human disease. Taken together, a reasonable conclusion can be that
reduced infiltration of macrophages might influence both atherosclerosis and
AAAs development.
However, there was a discrepancy between the results of the current
study and those of a previous study, which demonstrated that MMP-2 deficiency
was not protective for atherosclerosis and AAAs in apoE-/- mice (in Chapter 2).
Several potential mechanisms may explain the contradiction. First, the research
community is realizing that results obtained through analysis of gene function in
transgenic mice may differ from pharmacological interventions, which are
relatively short-termed. The transgenic animal may develop effective adaptations
to the long-term change regarding gene expression. For instance, deletion of an
isoform of NOS (nitric oxide synthase) led to an up-regulation of other NOS
isoforms in mice. In myoglobin null mice, an elevated capillary density was
observed which enhances the oxygen supply to tissues.72 Discrepancies
between results from clinical trials using a pharmacological blockade of integrins
for cancer therapy and results from animal studies utilizing the genetic deletion of
integrins provide an example of the contradiction in methods. This controversy
has raised a discussion of the potential role of these integrins in angiogenesis
and the safety and efficacy of integrin antagonists.
transplantation

experiment

is

similar

to

a

study

23

A bone marrow

utilizing

short-term

pharmacological treatment rather than the transgenic loss of gene function in the
animal.
Second, irradiation itself may influence the development of vascular
diseases. Ionizing irradiation is a risk factor for the development of
atherosclerosis via inducing the release of inflammatory cytokines. Moreover,
irradiation injures endothelial cells and increases vascular permeability. In the
current study, recipient mice received high dose gamma-irradiation, which might
influence the processes of atherosclerosis dramatically. It was reported that total
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body gamma irradiation and syngeneic bone marrow (BM) reconstitution
increased atherosclerosis area in the aortic root but decreased atherosclerosis
area in thoracic aorta in LDLr-/- mice fed with high fat diet for 16 weeks. The
reasons for this discrepancy remain unresolved.176 Unfortunately, there is not a
counterpart study in apoE-/- mice. In this dissertation project, we observed that,
after AngII-infusion, irradiated and syngeneic BM transplanted apoE-/- mice had
a tendency to have larger atherosclerotic plaques in the aortic root when
compared to non-irradiated mice (24.5 ± 6.7 x 10-3 mm2 vs. 10.0 ± 3.8 x 10-3
mm2; P = 0.114). There was a significant difference in the percentage of
atherosclerotic lesion to total surface area of aortic arch between irradiated and
BM transplanted mice and non-irradiated mice (6.7 ± 0.4% vs. 3.1 ± 0.8%; P <
0.001). These unpublished results affirm the effect of irradiation in human
atherosclerosis. We do not have saline control in the non-irradiated mice
because of limitations in the number of MMP-2 x apoE-/- mice available.
Irradiation might exacerbate inflammatory cell infiltration into the vessel
wall during atherosclerosis development, thereby, intensifying the beneficial
effect of impaired infiltration ability of MMP-2 deficient inflammatory cells.
Flanders et al. reported that mice lacking Smad3, which is a critical downstream
signaling molecule of TGF-beta, are protected against cutaneous injury induced
by ionizing radiation.
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TGF-beta is a potent chemotactic factor of monocytes,

and induces macrophage to secret cytokines. 208 As mentioned before, TGF-beta
can be activated by MMP-2. Although there is lack of an investigation in the role
of TGF-beta in irradiation-induced atherosclerotic lesion, a reduced local TGFbeta activation by MMP-2 deficient inflammatory cells might be protective.
There is lack of evidence suggest that ionizing irradiation is a risk factor of
AAAs. Some clinical studies suggest that beta-irradiation for the treatment of instent restenosis does not increase the aneurysm incidence in patients .196
However, there are several clinical trials which indicate that carotid artery
aneurysms can be induced by radiotherapy for head and neck cancer.
Histopathology findings of irradiation-induced aneurysm include carotid artery
necrosis and an incomplete and fragmented endothelial lining.

94

152, 177

The

exacerbation of inflammatory cell infiltration into the vascular wall might
contribute to irradiation-induced aneurysm formation as well.
The hematopoietic system contributes many cell types including
circulating leukocytes, resident macrophages in tissues and organs. Bone
marrow transplantation (BMT) technique using gene-targeted mice as donors
and recipients provides a useful approach to examine the contribution of
hematopoietic cell gene expression for diseases in vivo.
Some experiments suggest that resident progenitor cells in the adventitia
are the source of smooth muscle cells in atherosclerotic lesions, and bone
marrow progenitor cells hardly differentiate into resident cells in the vascular
wall.87 However, other studies suggest that hematopoietic stem cells can
differentiate into vascular cells, which take part in the pathogenesis of
atherosclerosis.173 This controversy might be due to the limitation of techniques
used to distinguish and determine the origin of stem cells in tissue and organs.
Although there are controversial opinions, it should be noted that bone marrowderived cells are progenitors that have high plasticity. Therefore, a bone marrow
transplantation experiment can be inherently flawed due to an inability to exclude
the contribution of other types of cells, such as endothelial cells
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and

VSMCs.173 Taken together, although it could not change the central conclusions
of this study as described above, irradiation and bone marrow transplantation
might influence the development of vascular diseases. This might contribute to
the apparent discrepancy between the findings of the current study and those of
a previous study (in Chapter 2).
Hemodynamic

conditions

regulate

vascular

remodeling,

monocyte

adhesion and transmural migration in murine AAA models.181 Although AngII
infusion dramatically increased mouse systolic blood pressure, MMP-2 deficiency
in bone marrow-derived cells did not ablate AngII-induced hypertension. This
indicates that the protective effect caused by the deletion of MMP-2 from bone
marrow-derived cells was not due to the control of blood pressure.
Interestingly, AngII infusion caused a significant rise in the number of
RBCs and a corresponding rise in the Hb levels in the blood of study mice.
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Several clinical observations suggest that AngII is responsible for inappropriately
sustaining production of erythropoietin despite hematocrit elevation, and is
capable of directly stimulating the erythroid progenitors in bone marrow to
produce erythrocytes.75,169 However, the mechanism is unclear. Another study
released an opposing result, stating that under physiological conditions in healthy
volunteers, increased concentrations of endogenous AngII is not a major factor of
erythropoietin regulation.
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In addition, MMPs/TIMPs are secreted by normal

human bone marrow hematopoietic cells and stromal cells and may play an
important role in intercellular cross-talk during hematopoiesis.132 To fully
understand the dramatic effects we have observed in the current study, the role
of MMP-2 in the regulation of behavior of stem cells should be considered.
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Table 5.1 Blood cell compositions of bone marrow-derived cell recipient mice
MMP-2 genotype
of BM
Infusion

MMP-2 +/+

MMP-2-/-

Saline

AngII

Saline

AngII

WBC
(1x103 cells/mm3)

10.1 ± 0.7

7.9 ± 0.9

8.1± 0.6

7.5 ± 1.1

RBC
(1x 106 cells/mm3)

9.3 ± 0.2

11.5 ± 0.3*

9.6 ± 0.1

11.0 ± 0.8*

Platelets
(1x103 cells/mm3)

992 ± 36

918 ± 61

1052 ± 40

976 ± 81

Hb (g/dl)

14.3 ± 0.3

16.7± 0.3*

14.5 ± 0.2

17.0 ± 0.5*

Data represent mean ± SEM for groups of 9-11 mice.
*P<0.001 with respect to saline infused mice of the same MMP-2 genotype
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Figure 5.1 Confirmation of MMP-2 genotype of bone marrow donors and
recipient mice (A) Gelatin zymography of extracts (15µg) of aortas of MMP-2+/+
and -/- x apoE-/- mice. No MMP-2 expression was detected in MMP-2 deficient
mice, whereas a prominent 72kDa band of gelatin lysis by MMP-2 was present in
the MMP-2 wild type mice. (B) Representative PCR genotyping of bone marrow
removed from recipient mice transplanted with either MMP-2+/+ or -/- bone
marrow-derived cells. The 1.1 kbp (for the mutant allele) band was detected in
the DNA of bone marrow from MMP-2-/- bone marrow recipient mice and was
absent in bone marrow of the control transplanted mice.
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Figure 5.2 Effect of bone marrow-derived cell transplantation and AngII
infusion on the body weight of recipient mice. There was no effect of MMP-2
genotype in bone marrow-derived cells on the body weight of the study mice.
However, AngII infusion caused a significant loss of body weight compared with
saline infusion (*P < 0.001). Points represent the means of 14 -16 mice and bars
are SEM.
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Figure 5.3 Effect of bone marrow-derived cell transplantation and AngII
infusion on the blood pressure of recipient mice. Mini-pumps filled with saline
or AngII (1,000 ng/kg/min) were implanted subcutaneously into the mice at day 0
(n = 10-11/group). Saline infusion did not change systolic blood pressure of the
recipient mice. There was a significant change in blood pressure during AngII
infusion in the treated mice. A repeating ANOVA was used to analyze this data
(#P < 0.0001 for comparisons of AngII versus saline infusion within MMP-2
genotypes; †P < 0.001 for analysis of the interaction between AngII infusion and
time within AngII treated mice). Points represent the means of measurements of
each week and bars are SEM.
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Figure 5.4 Effect of bone marrow-derived cell transplantation and AngII
infusion on the total cholesterol plasma concentration of recipient mice.
Serum total cholesterol concentrations were measured using commercially
available enzymatic assay kits. There was no significant difference in serum
cholesterol concentrations across groups (n = 9-10/group). Histobars represent
the means and bars are SEM. BM stands for bone marrow.
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Figure 5.5 Effect of bone marrow-derived cell transplantation and AngIIinfusion on the lipoprotein distribution of recipient mice. Lipoprotein
distribution of mice was resolved using size exclusion chromatography, namely,
fast performed lipid chromatography (FPLC). The curves of VLDL, LDL/IDL and
HDL of the mice were overlapped. Points represent the means of 9-10 individual
mice, and bars are SEM. S is saline-infused mice; A is AngII-infused mice.
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Figure 5.6 Effect of bone marrow-derived cell transplantation on AngIIinduced hypertrophy on the aortic arch of recipient mice. AngII infusion
caused a significant increase in the intima area of the aortic arch of the recipient
mice. There was no difference between MMP-2+/+ and -/- bone marrow-derived
cell recipient mice. Values obtained from individual mice are represented as open
symbols, the means are represented as closed symbols and SEM as bars. (n =
10-11/group; # P < 0.001 for comparisons of AngII versus saline infusion within
MMP-2 genotypes) BM stands for bone marrow.
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Figure 5.7 Representative light photomicrographs of luminal surface of
aortic arch and thoracic aortas of the recipient mice. The aortas were stained
with Oil Red O. Red-stained areas are atherosclerotic lesions. AngII-infusion (E
and G) accelerates atherosclerosis development in mice as compared to saline
infusion (A and C). MMP-2-/- bone marrow cell recipient mice (C and G) have
reduced atherosclerotic lesion as compared to MMP-2+/+ bone marrow cell
recipient mice (A and E). B, D, F, and H show the detail of boxed area in A, C, E,
and G, respectively.
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Figure 5.8 Effect of bone marrow-derived cell transplantation on AngIIinduced atherosclerosis on the intima of the aortic arch and thoracic aorta
of recipient mice. The percentage of the intimal area covered by atherosclerotic
lesion was quantified in the aortic arch and thoracic aorta. Infusion of AngII
increased the area of atherosclerosis in both MMP-2 +/+ and -/- bone marrowderived cell recipient mice. There was a significant reduction in AngII-induced
atherosclerosis in MMP-2-/- BM-derived cells recipient mice compared to MMP2+/+ BM-derived cells recipient mice (n = 10-11/group; ** P < 0.001 for
comparisons of MMP-2 -/- versus MMP-2+/+ within AngII infused groups; † P <
0.001 for comparisons of AngII versus saline infusion within MMP-2+/+ mice; ††
P < 0.01 for comparisons of AngII versus saline infusion within MMP-2 -/- mice.
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Figure 5.9 Effect of bone marrow-derived cell transplantation on AngIIinduced atherosclerosis in aortic roots of recipient mice Reduced severity of
atherosclerosis was observed in the sections of aortic root in mice with MMP-2-/bone marrow-derived cells. Values obtained from individual mice are represented
as open symbols, the means are depicted as closed symbols and SEM as bars.
(n = 8/group; *P < 0.01 for comparisons of MMP2+/+ versus -/- within AngII or
saline infused groups; †P < 0.01 for comparisons of AngII versus saline infusion
within MMP-2+/+ mice)
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Figure 5.10 Effect of bone marrow-derived cell transplantation on
macrophage infiltration in AngII-induced atherosclerosis in aortic roots
from recipient mice Representative photomicrographs of immunohistochemical
staining for macrophage on cross-cryosections of aortic roots were shown.
Staining was less pronounced in MMP-2-/- bone marrow cell recipient mice (B)
as compared to MMP-2+/+ bone marrow recipient mice (A). This indicates a
reduced macrophage infiltration in the atherosclerotic lesions in MMP-2-/- bone
marrow cell recipient mice. However, it might be due to a reduced size of
atherosclerosis in these mice. Bars indicate 50 µm. C and D show the detail of
boxed area in A and B, respectively.
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Figure 5.11 Effect of bone marrow-derived cell transplantation on the
incidence of AngII-induced AAAs in recipient mice The absence of MMP-2 in
bone marrow-derived cells decreased the incidence of AngII-induced AAA in
apoE -/- mice compared with MMP-2 wild type bone marrow transplanted mice.
(n = 14-17 per group; *P < 0.05) BM is for bone marrow.
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Figure 5.12 Effect of bone marrow-derived cell transplantation on the
severity of AngII-induced AAAs in recipient mice Abdominal aortas were
isolated by cutting the aorta at the level of the diaphragm and the iliac bifurcation.
The tissue was weighed to provide an index of AAA severity. Values obtained
from individual mice are represented in open symbols, the means are shown as
closed symbols and SEM as bars (n = 14-16 per group). These data do not
include the tissue weight of two mice (both were MMP-2+/+ bone marrow cell
recipient mice) that died from AAA rupture during AngII infusion. * P < 0.05 for
comparisons of MMP2+/+ versus -/- within AngII infused mice; #P < 0.01 for
comparisons of AngII versus saline infusion within mice with same MMP-2
genotypes
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Chapter Six
General Discussion and Future Studies
Atherosclerosis and AAAs are distinguishable, vascular diseases that
have some common features. For example, they share certain risk factors such
as smoking, aging, and male gender. Furthermore, population-based studies
demonstrate that a considerable number of patients with AAAs have a history of
atherosclerosis.

Two

prominent

pathological

characteristics

of

both

atherosclerosis and AAAs are the infiltration of inflammatory cells (especially
macrophages and lymphocytes) into the vascular wall and the remodeling of the
extracellular matrix (ECM) at the site of inflammation.63,170 Proteases, especially
MMPs, and cytokines play key roles in these pathological processes.
There is evidence that MMP-2 is involved in atherosclerosis and AAA
formation. Primarily, the secretion and activation of MMP-2 is elevated in both
atherosclerosis and AAA lesions.43,74 Also, abluminal application of CaCl2induced AAA formation was ablated in MMP-2 knock out mice.126 MMP-2
deficiency led to reduced intimal hyperplasia in mouse carotid artery blood flow
cessation model as well.101,114 The understanding of the mechanism behind
these results is still superficial, although some hypothesize that MMP-2 functions
in ECM remodeling and facilitating cell migration by destroying the barrier around
the cell.
The primary purpose of the current dissertation project was to evaluate the
general hypothesis that MMP-2 plays an important role in hyperlipidemia and
AngII-induced atherosclerosis and AAAs. We also sought to determine if there is
a greater role of MMP-2 beyond just the cleavage of elastin. By using apoE-/double knockout mice in this project, we were able to evaluate the role of MMP-2
deficiency in hyperlipidemia as well as atherosclerosis. Four studies were
completed to test the overall hypothesis.
First, we investigated the development of atherosclerosis and AngIIinduced AAAs in MMP-2-/- and MMP+/+ mice on an apoE-/- background. It was
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surprising that MMP-2 deficiency did not reduce the incidence of AngII-induced
AAAs or the size of atherosclerotic lesions in apoE-/- mice. However, the cellular
and ECM content of atherosclerotic plaques was modified in MMP-2-/- x apoE-/when compared to MMP-2+/+ x apoE-/- control mice. To explain the apparent
paradox between this result and the hypothesis, we investigated the
morphological characteristics of the aortic wall of MMP-2-/- mice in a
hyperlipidemic background. We detected an enhanced MMP-9 level in the aortic
wall of MMP-2-/- x apoE-/- mice compared with MMP-2+/+ x apoE-/- mice.
Interestingly, we also observed more branches in the elastin fibers of the aortic
wall from MMP-2-/- mice when compared with aortic walls of wild type mice.
Next, we examined the behavior of macrophages of MMP-2-/- mice. Reduced
adhesion, migration and expression of integrin beta 3 were detected in the
macrophages of MMP-2 deficient mice when compared with the macrophages of
wild type control mice. Lastly, to examine whether MMP-2 deficiency in bone
marrow-derived cells could influence AAAs and atherosclerosis, we implemented
a phase of bone marrow transplantation. There was a significant reduction of
both atherosclerosis development and AAAs formation in mice receiving
reconstituted MMP-2-/- bone marrow cells.
The most encouraging finding in this dissertation project is that bone
marrow cell-derived MMP-2 is critical in AngII-induced AAAs and atherosclerosis
in apoE-/- mice. In spite of enhancing MMP-9 expression (mainly in an inactive
form), the peritoneal macrophages of MMP-2-/- mice have an impaired adhesion
and invasion ability, which might be due to a reduced integrin beta 3 expression.
Consistent with this finding, it was reported that a 10-fold increase in the inactive
form of MMP-9 in macrophages by gene transfection did not reduce the
atherosclerotic lesion in apoE deficient mice (Data presented by P. Gough at the
6th annual conference on Atherosclerosis, Thrombosis and Vascular Biology,
2005). Although MMP-9 can be activated by several serine proteinases, the
active form of MMP-2, generated after the activation of TIMP-2-free proMMP-2
on the cell surface, might activate proMMP-9. Based on our findings, we
concluded that MMP-2 deficiency in bone marrow-derived cells reduced AngII-
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induced AAAs and atherosclerosis, and this reduction might be due to reduced
adhesion and migration ability of macrophages. According to the shortcomings of
MMP inhibitors, such as toxicity and lack of specificity, these findings could lead
to new targeted-molecular approaches to the prevention and treatment of
atherosclerosis and AAAs.
At first, it seems that there is a contradiction between the dramatic
protective effect from MMP-2 deficiency in bone marrow-derived cells and the
data we obtained from the study of MMP-2-/- x apoE-/- mice, in which MMP-2
deficiency did not reduce the incidence of AAAs or the size of atherosclerosis.
However, this discrepancy might provide an insight into the importance of the
interaction among various cell types and MMPs in the development of vascular
diseases. There are two hypotheses which may account for this discrepancy: 1)
MMP-2 produced by resident cells of the vessel wall (especially SMCs) is
supplemental in atherogenesis and AAA formation and 2) the overexpression of
MMP-9 in SMCs is critical for atherosclerosis and AAA formation in apoE-/- mice,
but the overexpression of MMP-9 in macrophages is not.
Although inflammatory cells play a pivotal role in the initiation and
progression of both diseases, the participation of other cell types, especially
VSMCs and endothelial cells, is critical as well. In AAAs, VSMCs play a key role
in the remodeling of aortic wall. VSMCs synthesize matrix proteins, such as
collagen, elastin, and proteoglycans. They also secrete proteolytic enzymes,
including MMPs, that digest the matrix proteins and turnover the ECM of the
aortic wall. In rats, implantation of VSMCs prevented AAA formation in an aortic
xenograft model.4 Proliferation and migration of VSMCs in the subendothelial
space is a prominent pathological feature of atherosclerotic lesions. Multiple
MMPs (including MMP-2 and 9) are involved in the migration of VSMCs.
Although MMP-2 and MMP-9 have a redundancy in their substrate profile, it is
possible that they bind to a diverse range of receptors and elicit different patterns
of cell behaviors in various types of cell. On the basis of our study, we concluded
that integrin alpha v beta 3 might serve as a receptor for MMP-2 on the
macrophage membrane. This conclusion is supported by our data suggesting
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that TSRI265 reduced the invasion ability of MPMs. Enhanced MMP-9
expression did not reconstitute this adhesion ability in MMP-2 deficient
macrophages. Although MMP-9 is produced in relatively small amounts by
VSMCs when compared to MMP-2, it appears to regulate smooth muscle cell
adhesion and migration through its interaction with CD44, a hyaluronan
receptor.101 Taken together, these data highly suggested that MMPs bind to
various receptors and influence cell behaviors through autocrine and/or paracrine
pathways. However, more studies must be done to elucidate mechanisms
underlying the interaction and regulation of these enzymes and their receptors to
verify these hypotheses. In MMP-2-/- x apoE-/- mice, the increased MMP-9
expression in the endothelium and/or VSMCs might overwhelm the beneficial
effect from MMP-2 deficiency in macrophages.
MMP-2 might influence the proliferation and apoptosis of VSMCs as well.
First, the proliferation of VSMCs is elicited by multiple growth factors, such as
TGF-beta, IGF, and bFGF, through autocrine and/or paracrine pathways.12
Although the mechanisms underlying these pathways are not fully understood, it
is reasonable to hypothesize that MMP-2 might be involved in the VSMCs
proliferation through modifying the activity of growth factors. Second, MMPs
might process and release the Fas ligand (FasL), which is an integral membrane
protein homologous with TNF and mediates apoptosis of Fas+ target cells, in a
soluble form (sFasL). Treatment with inhibitors of MMPs led to a reduction of
sFasL and an accumulation of membrane-type Fas ligand (mFasL).102,105,198
sFasL, lacking transmembrane and cytoplasmic domains, is a poor mediator of
apoptosis, whereas full-length mFasL is pro-apoptotic. sFasL derived from
monocytes/macrophages and endothelial cells induces VSMCs apoptosis.18 This
apoptotic effect from deregulation of growth factors and/or ablation of FasL
processing might contribute to the diminished protection from AngII-induced
AAAs in MMP-2 deficient, hyperlipidemic mice. More studies need to be done to
test these hypotheses in future.
As mentioned in Chapter Three, two potential mechanisms might underlie
the enhancement of MMP-9 expression in the aortic wall of MMP-2-/- x apoE-/-
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mice. First, there might be compensatory overproduction MMP-9 in mice with
MMP-2 gene deficiency. Second, it was reported that the MT1-MMP/TIMP2/MMP-2 complex, in addition to facilitating activation of pro-MMP-2, could be
involved in regulating the expression of MMP-9.53 This indicates that MMP-2
might be a critical component in the regulation of MMP-9 expression.
Both ECM remodeling and inflammatory cell recruitment are important for
the maintenance of normal vascular physiological functions, such as healing
post-injury. As a constitutively expressed enzyme, MMP-2 is involved in both
processes. However, under pathological conditions, these processes might
become overactive and shift to being harmful rather than protective for blood
vessels, facilitating the development of atherosclerosis and AAAs. Therefore, a
temporal or spatial regulation of MMP-2 instead of a simple deletion of the MMP2 gene might emerge as a desired prophylaxis and treatment of vascular
diseases. To reach this goal, a full understanding of the redundant ECM
proteolytic mechanisms (i.e. why are so many proteolytic enzymes involved in
the remodeling of vascular wall?) in the development of vascular diseases is also
critical. This requires the further understanding of the physiopathological specific
situation, the cooperation of diverse types of cells, and the stimuli which induce
synthesis and/or activation of individual MMPs in vascular diseases as well.
Through careful research and evaluation, the importance of MMP-2 in
cardiovascular diseases has been realized in the last decade. Traditionally,
MMP-2 was thought to release cells from the ECM simply by its elastiolytic
capability. However, the role of MMP-2 in ECM degradation may be more
complex. Combined with the realization of the critical role of ECM in regulating
signaling molecules for cell behaviors, other insights were taken into the
evaluation of the potential role of ECM-digestive enzymes in both physiological
and pathological processes. Our major findings in the current dissertation support
that the role of MMP-2, which is an important extracellular protease and
constitutively expressed in vascular wall, goes far beyond that of remodeling the
ECM only. MMP-2 can be involved in the regulation of cell behaviors as well.
This new perspective may lead to exciting new approaches in the intervention of
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cardiovascular diseases. It could be pivotal in understanding the subtle
interaction involved in cell-to-matrix and cell-to-cell interaction. However, future
studies will have to determine the pathways required by these enzymes for the
activation and regulation of various cell types under diverse physiopathological
conditions. These studies might contribute to a further understanding of the role
of MMP-2 in vascular diseases.
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ABBREVIATIONS
AA

amino acid

AAA

abdominal aortic aneurysm

ACE

angiotensin-converting enzyme

AngII

angiotensin II

apoE

apolipoprotein E

BM

bone marrow

BP

blood pressure

CD

cluster differentiation

CHD

coronary heart disease

ECM

extracellular matrix

EGF

epidermal growth factor

EPC

endothelial progenitor cell

ET

endothelin

FACS

fluorescence activated cell sorting/flow
cytometry

FGF

fibroblast growth factor

Hb

hemoglobin

HDL

high density lipoprotein

ICAM

intercellular adhesion molecule

IGF

insulin-like growth factor

IGFBP

insulin-like growth factor binding protein

LDL

low density lipoprotein

IL

interleukin

LRP

low density lipoprotein-related protein

MCP-1

macrophage chemoattractant protein-1

MMP

matrix metalloproteinase

MPM

mouse peritoneal macrophage

MT-MMP

membrane type-MMP

O.C.T.

optimal cutting temperature
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Opn

osteopontin

ox-LDL

oxidized LDL

PAI-1

plasminogen activator inhibitor-1

PCAM

platelet endothelial cellular adhesion molecule

PCR

polymerase chain reaction

PDGF

platelet-derived growth factor

PG

prostaglandin

RAAS

renin-angiotensin-aldosterone system

RAP

receptor-associated protein

RBC

red blood cell

ROS

reactive oxygen species

RT

room temperature

RT-PCR

reverse transcription polymerase chain
reaction

TC

total cholesterol

TGF

transforming growth factor

TIMP

tissue inhibitor of matrix metalloproteinase

tPA

tissue plasminogen activator

uPA

urokinase-type plasminogen activator

VCAM

vascular cell adhesion molecule

VEGF

vascular endothelial growth factor

VSMC

vascular smooth cell

WBC

white blood cell
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